Systems and methods for identifying an access port

Abstract
An access port for subcutaneous implantation is disclosed. Such an access port may comprise a body for capturing a septum for repeatedly inserting a needle therethrough into a cavity defined within the body. Further, the access port may include at least one feature structured and configured for identification of the access port subsequent to subcutaneous implantation. Methods of identifying a subcutaneously implanted access port are also disclosed. For example, a subcutaneously implanted access port may be provided and at least one feature of the subcutaneously implanted access port may be perceived. Further, the subcutaneously implanted access port may be identified in response to perceiving the at least one feature. In one embodiment, an identification feature is engraved or otherwise defined by the access port, so as to be visible after implantation via x-ray imaging technology.
Description
BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A shows a perspective view of an embodiment of an access port according to the instant disclosure;



FIG. 1B shows a schematic side cross-sectional view the access port shown in FIG. 1A;



FIG. 2 shows a perspective view of an embodiment of an access port according to the instant disclosure;



FIG. 3 shows a perspective view of an access port according to the instant disclosure;



FIG. 4 shows a perspective view of an access port according to the instant disclosure;



FIG. 5 shows a perspective view of an access port according to the instant disclosure;



FIG. 6A shows a perspective view of an access port according to the instant disclosure;



FIG. 6B shows a side view of the access port shown in FIG. 6A;



FIG. 7 shows a perspective view of an access port according to the instant disclosure;



FIG. 8 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;



FIG. 9 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;



FIG. 10 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;



FIG. 11 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;



FIG. 12 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;



FIG. 13 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;



FIG. 14 shows a simplified perspective view of a cap for forming an access port according to the instant disclosure;



FIG. 15A shows a perspective view of an embodiment of an access port according to the instant disclosure;



FIG. 15B shows a top elevation view of the access port shown in FIG. 15A;



FIG. 16 shows a perspective view of an access port according to the instant disclosure;



FIG. 17 shows a perspective view of an access port according to the instant disclosure;



FIG. 18 shows a perspective view of an access port according to the instant disclosure;



FIG. 19 shows a perspective view of an access port according to the instant disclosure;



FIG. 20 shows a perspective view of an access port according to the instant disclosure;



FIG. 21 shows a perspective view of an access port according to the instant disclosure;



FIG. 22 shows a perspective view of another embodiment of an access port according to the instant disclosure;



FIG. 23 shows a top elevation view of the assembled access port shown in FIG. 22;



FIG. 24 shows a simplified representation of a transverse cross section of the access port shown in FIGS. 22 and 23;



FIGS. 25-51 show perspective views of additional embodiments of an access port;



FIG. 52 shows a bottom perspective view of an access port according to one embodiment;



FIG. 53A shows a top view of the access port shown in FIG. 52;



FIG. 53B shows a bottom view of the access port shown in FIG. 52;



FIG. 54A represents a radiographic image of the access port shown in FIG. 52 when viewed from above the access port;



FIG. 54B represents a radiographic image of the access port shown in FIG. 52 when viewed at an angle of approximately 20 degrees;



FIG. 54C represents a radiographic image of the access port shown in FIG. 52 when viewed at an angle of approximately 50 degrees;



FIG. 55 shows a cross-sectional view of the access port shown in FIG. 52;



FIGS. 56A and 56B show cross-sectional views of example embodiments of engraved features on an access port surface;



FIG. 57A shows a top perspective view of an access port according to one embodiment;



FIG. 57B shows a bottom perspective view of the access port shown in FIG. 57A;



FIG. 57C shows a bottom view of the access port shown in FIG. 57A;



FIG. 58A shows a top perspective view of another embodiment of an access port;



FIG. 58B shows a bottom perspective view of the access port shown in FIG. 58A;



FIG. 58C shows a bottom view of the access port shown in FIG. 58A;



FIG. 59A shows a side view of an embodiment of an access port;



FIG. 59B shows a bottom view of the access port shown in FIG. 59A;



FIG. 60A shows a bottom perspective view of an additional embodiment of an access port;



FIG. 60B shows a bottom view of the access port shown in FIG. 60A;



FIG. 61A shows a bottom perspective view of an additional embodiment of an access port;



FIG. 61B shows a bottom view of the access port shown in FIG. 61A;



FIG. 62A shows a bottom view of an additional embodiment of an access port;



FIG. 62B shows a side view of the access port shown in FIG. 62A;



FIG. 62C shows an end view of the access port shown in FIG. 62A;



FIG. 63A shows a bottom view of another embodiment of an access port;



FIG. 63B shows a side view of the access port shown in FIG. 63A;



FIG. 63C shows an end view of the access port shown in FIG. 63A;



FIG. 64 shows a top view of an access port according to one embodiment;



FIG. 65 shows a perspective view of an access port according to one embodiment;



FIGS. 66A-66D show various views of an access port according to one embodiment;



FIG. 67 shows a bottom perspective view of an access port according to one embodiment;



FIGS. 68A-68C show various views of a septum of an access port according to one embodiment;



FIG. 69 shows a perspective view of an access port according to one embodiment;



FIG. 70 shows a perspective view of an identifier for an access port according to one embodiment;



FIG. 71 shows a top view of an identifier for an access port according to one embodiment;



FIG. 72 shows a perspective view of a port and a catheter including an identifier according to one embodiment;



FIGS. 73A and 73B show various views of an identifier for an access port according to one embodiment;



FIGS. 74A and 74B show views of an identifier for an access port according to one embodiment; and



FIGS. 75A-75C show various views of an identifier for an access port according to one embodiment.







DETAILED DESCRIPTION

The instant disclosure relates generally to percutaneous access and, more specifically, to methods and devices associated with percutaneous access. Generally, the instant disclosure relates to an access port for subcutaneous implantation. In one embodiment, an access port may allow a physician or other medical personnel to obtain long term percutaneous access to the interior of a patient's body. Employing an access port for percutaneous access may reduce the opportunity for infection by inhibiting fluid connections (that extend into the interior of a patient's body) from the patient's skin and from the external environment. The access device allows access to the interior of the patient without requiring a needle to pierce the skin. Further, internal components, such as a catheter or a valve, may be replaced without a surgical procedure. Features or aspects of the instant disclosure may apply to any such access ports for subcutaneous access to a patient, without limitation. The access port may be injected by hand (e.g., via a syringe including a needle) for example, or may be injected and pressurized by mechanical assistance (e.g., a so-called power injectable port).


Power injectable ports may be employed in, among other processes, for example, computed tomography (“CT”) scanning processes. More particularly, a so-called “power injector” system may be employed for injecting contrast media into a peripherally inserted intravenous (IV) line. For example, such power injectors or injection systems may be commercially available from Medrad, Inc., a subsidiary of Schering AG, Germany and may be marketed under the trademark STELLANT®. Because fluid infusion procedures are often defined in terms of a desired flow rate of contrast media, such power injection systems are, in general, controllable by selecting a desired flow rate.


More specifically, the instant disclosure relates to an access port having at least one perceivable or identifiable feature for identifying the access port, wherein the identifiable feature is perceivable after the access port is implanted within a patient. For example, at least one or perhaps multiple identifiable feature(s) of an access port contemplated by the instant disclosure may be correlative to information (e.g., a manufacturer's model or design) pertaining to the access port. Thus, an identifiable feature from an access port of a particular model may be unique in relation to most if not all other identifiable features of another access port of a different models or design. Of course, the at least one identifiable feature of an access port contemplated by the instant disclosure may be further correlative with any information of interest, such as type of port, catheter type, date of manufacture, material lots, part numbers, etc. In one example, at least one identifiable feature of an access port may be correlative with the access port being power injectable. In this way, once at least one identifiable feature of an access port is observed or otherwise determined, correlation of such at least one feature of an access port may be accomplished, and information pertaining to the access port may be obtained.


In one embodiment, at least one feature may be perceived by palpation (i.e., to examine by touch), by way of other physical interaction, or by visual observation. Accordingly, a person of interest may touch or feel the access port through the skin to perceive at least one identifying characteristic thereof. In another embodiment, at least one identifiable feature may be perceived via x-ray or ultrasound imaging. In yet a further embodiment, at least one identifiable feature may be perceived through magnetic, light, or radio energy interaction or communication with the access port.


Turning to the embodiment wherein at least one feature may be perceived through palpation, other physical interaction, or visual observation, a topography or exterior surface feature of an access port contemplated by the instant disclosure may be configured for perception. For example, referring to FIGS. 1A and 1B, an exemplary access port 10 contemplated by the instant disclosure is shown. FIGS. 1A and 1B show a perspective view and a schematic side cross-sectional view, respectively, of an access port 10 for allowing percutaneous or otherwise internal access to a patient's body. Access port 10 includes a housing or body 20 defined by a cap 14 and a base 16. Cap 14 and base 16, as known in the art, may be configured for capturing therebetween a septum 18. As shown in FIG. 1A, cap 14 and base 16 may matingly engage one another along a mating line 15. Cap 14 and base 16 may be secured or affixed to one another via mechanical fasteners such as screws or other fastening devices, may be adhesively affixed to one another, or may be affixed to one another as known in the art. Further, cap 14, base 16, and septum 18 may collectively define a cavity 36 in fluid communication with a lumen 29 of outlet stem 31.


The body 20 may be implanted in a patient 7, as shown in FIG. 1B, to dispose the cavity 36 subcutaneously within the patient 7. Also, suture apertures 66 (FIG. 1A) may be used to affix the access port 10 within the patient 7, if desired. After the body 20 is implanted in a patient 7, the upper surface of the septum 18 may be substantially flush with the surface of the skin 6 of the patient 7 and may be repeatedly punctured for creating a percutaneous passageway from the exterior of the skin of the patient into the cavity 36. The outlet stem 31 may create a fluid-communicative passageway from the cavity 36 through the outlet stem 31 and into the interior of the patient 7. A catheter may be coupled to the outlet stem 31 for fluid communication with the cavity 36 and for transferring fluid from the cavity 36 to a desired remote location from the cavity 36 and within a patient 7.


Body 20 of access port 10 may comprise a bio-compatible material such as polysulfone, titanium, or any other suitably bio-compatible material as known in the art. Accordingly, the body 20 may be formed from a bio-compatible plastic material. If desired, the body 20 may comprise a penetrable material for penetration by sutures or needles. In another embodiment, and as discussed further hereinbelow, body 20 may comprise an impenetrable material such as, for instance, a metal if desired. Body 20 may include a concave bottom or, in another embodiment, may include a flat bottom, without limitation.


According to the instant disclosure, access port 10 may comprise a body 20 exhibiting at least one identifiable feature. More particularly, as shown in FIG. 1A, body 20 may exhibit a partial generally pyramidal shape (i.e., a polygonal base having surfaces for each side of the polygon extending toward a common vertex otherwise known as a frustum). Generally, a body 20 of an access port 10 may exhibit a partial pyramidal shape extending between a generally quadrilateral shaped base positioned at reference plane 11 and a generally quadrilateral shaped upper base positioned at reference plane 9. Reference planes 9 and 11 will not be shown in FIGS. 2-21, for clarity; however, reference to planes 9 or 11 with respect to FIGS. 2-21, as used herein, will refer to corresponding reference planes analogous to reference planes 9 and 11 as shown in FIGS. 1A and 1B.


As shown in FIG. 1A, the exterior of access port 10 is substantially defined by four substantially planar side surfaces 50 connected to one another by radiuses 32. In addition, the upper topography 61 of access port 10 is defined by upper surface 60 in combination with chamfers 46A and 46B and may be further defined by the upper surface of septum 18. Explaining further, the outer periphery of upper topography 61 may be described as a generally quadrilateral exterior formed by side regions 54 and having rounded corner regions 30 adjacent side regions 54. Such a configuration may provide an access port having at least one feature that may be perceived by palpation.


It may be appreciated that there are many variations to the geometry of access port 10 as shown in FIG. 1A. For instance, while the body 20 of access port 10 may be described as a partially pyramidal shape or frustum, the instant disclosure is not so limited. Rather, one or more of side surfaces 50 may be oriented at as may be desired, without reference to any other side surfaces 50. Accordingly, for example, one of surfaces 50 may be substantially vertical while the remaining surfaces 50 may be oriented at respective, selected angles. Furthermore, it should be understood that FIG. 1A is merely exemplary and that the dimensions and shape as shown in FIG. 1A may vary substantially while still being encompassed by the instant disclosure.



FIG. 2 shows a perspective view of another embodiment of access port 10 according to the instant disclosure. As shown in FIG. 2, the exterior of access port 10 is substantially defined by a generally parallelogram-shaped base (positioned at reference plane 11 as shown in FIGS. 1A and 1B) extending generally pyramidally to a generally parallelogram-shaped upper surface (positioned at reference plane 9 as shown in FIGS. 1A and 1B). As shown in FIG. 2, radiuses 42 may be larger than radiuses 32 as shown in FIG. 1A. Furthermore, the upper topography 61 of access port 10 as shown in FIG. 2 may include rounded corner regions 40 which are larger than rounded corner regions 30 as shown in FIG. 1A. Thus, FIG. 2 shows an exemplary embodiment of an access port 10 that may be perceivably distinguishable from access port 10 as shown in FIGS. 1A and 1B. For example, a difference between one exterior of an access port contemplated by the instant disclosure and another exterior of a different access port contemplated by the instant disclosure may be determined by way of palpation.


In another embodiment, in another aspect contemplated by the instant disclosure, a template may be employed for perceiving at least one feature of an access port. For instance, a complementarily-shaped template may be positioned over and abutted against an access port contemplated by the instant disclosure so as to determine if the access port matches or substantially corresponds to the shape of the template. Such a process may reliably indicate or perceive at least one feature of an access port contemplated by the instant disclosure. Of course, a plurality of templates corresponding to different models of access ports may be serially engaged with an unknown access port so as to perceive at least one feature thereof. Such a process may allow for identification (e.g., of a model or manufacturer) of an access port contemplated by the instant disclosure.


In another aspect contemplated by the instant disclosure, an upper topography of an access port may include at least one feature for identifying the access port. For example, as shown in FIG. 3, upper surface 60 of access port 10 may be nonplanar. More specifically, upper surface 60 may be tapered or may arcuately extend downwardly (i.e., toward reference plane 11 as shown in FIGS. 1A and 1B) as it extends radially inwardly toward septum 18. Otherwise, access port 10, as shown in FIG. 3, may be configured substantially as described hereinabove with reference to FIGS. 1A and 1B. Thus, upper surface 60 is one exemplary example of at least one perceivable feature for identification of an access port contemplated by the instant disclosure.


In yet a further embodiment of an access port contemplated by the instant disclosure, side regions 54 extending between rounded corner regions 30 may exhibit at least one perceivable feature. For example, as shown in FIG. 4, access port 10 may include one or more side regions 54 that extend arcuately between adjacent rounded corner regions 30. Otherwise, access port 10, as shown in FIG. 4, may be configured substantially as described hereinabove with reference to FIGS. 1A and 1B. Side regions 54 may be congruent or symmetric with respect to one another or, in another embodiment, may be configured differently with respect to one another, without limitation.



FIG. 5 shows a further exemplary embodiment of an access port contemplated by the instant disclosure. More specifically, access port 10, as shown in FIG. 5, includes side regions 54 that form recessed regions 72 between adjacent rounded corner regions 30. Put another way, the upper topography 61 may include alternating recessed regions 72 and protruding regions 70 positioned generally about a periphery of septum 18. Otherwise, access port 10, as shown in FIG. 5, may be configured substantially as described hereinabove with reference to FIGS. 1A and 1B. Such a configuration may provide an access port having at least one identifiable feature.


In a further embodiment of an access port contemplated by the instant disclosure, FIGS. 6A and 6B show a perspective view and a side view, respectively, of an access port 10 generally configured as is described with reference to FIG. 5 but having an elongated body 20E. More specifically, elongated body 20E of access port 10, as shown in FIGS. 6A and 6B, includes a side surface 50E that extends generally from upper topography 61 downwardly (i.e., toward reference plane 11 as shown in FIGS. 1A and 1B) and having a slope (e.g., an angle with respect to a vertical axis normal to an upper surface of septum 18) which is different from the other side surfaces 50. Otherwise, access port 10, as shown in FIG. 6, may be configured substantially as described hereinabove with reference to FIGS. 1A and 1B. Such a configuration may provide an elongated body 20E of an access port 10 having an elongated side portion.


Of course, one or more side surfaces of an access port according to the instant disclosure may be configured for forming a body exhibiting a selected shape as may be desired. An elongated body portion of an access port contemplated by the instant disclosure may form, in combination with other features as described hereinabove or, in another embodiment, taken alone, at least one perceivable feature for identification of an access port according to the instant disclosure.



FIG. 7 shows a further embodiment of an access port encompassed by the instant disclosure. Particularly, as shown in FIG. 7, access port 10 may include an upper body portion 20a and a lower body portion 20b. Furthermore, each of upper body portion 20a and lower body portion 20b may exhibit a partial pyramidal shape (i.e., a frustum), wherein the body portions 20a and 20b are stacked vertically with respect to one another. Accordingly, upper body portion 20a may form an overhanging rim feature 76 extending along a periphery of access port 10. Explaining further, lower body portion 20b may have an exterior substantially defined by side surfaces 50b and rounded corner regions 30b, while upper body portion 20a may have an exterior substantially defined by side surfaces 50a, rounded corner regions 30a, and upper topography 61. It may be appreciated that overhanging rim feature 76 may be sized and configured for perception via palpation. Such a configuration may provide a suitable access port for delivery of a beneficial or medicinal substance, the access port being identifiable (e.g., by model number, manufacturer, etc.) after implantation.


It should be understood that the instant disclosure contemplates access ports having an exterior geometry that is not quadrilateral in nature. Rather, the instant disclosure contemplates that an access port may have an exterior which is generally cylindrical, generally conical, generally elliptical, generally oval, or an exterior that is otherwise arcuate in nature. Specifically, the instant disclosure contemplates that an access port having a substantially rounded or arcuate exterior may include at least one feature configured for identification of the access port after implantation. For example, as shown in FIG. 8, shows a cap 14 that exhibits an exterior surface 78 that is substantially conical. Cap 14 may be assembled to a suitable base (not shown) for capturing a septum (not shown) as described hereinabove to form an access port 10 as generally described with reference to FIGS. 1-7.


The instant disclosure further contemplates that at least one protrusion, protruding region, recess, recessed region, undulation, or adjacent features of different elevation may comprise a feature for identifying an access port contemplated by the instant disclosure. More specifically, upper topography 61C, as shown in FIG. 8, may include a plurality of protrusions 80. Protrusions 80 may exhibit partially spherical upper surfaces that transition into a lower portion of cap 14. In further detail, protrusions 80 may be circumferentially spaced about the periphery of septum (not shown) as may be desired. In one embodiment, a plurality of protrusions 80 may be symmetrically circumferentially spaced about the periphery of septum (not shown). More generally, at least one protrusion 80 may be sized, configured, and positioned for forming at least one identifiable feature of an access port. Of course, at least one protrusion 80 may be structured for facilitating comfort of a patient within which the access port is implanted. As may be appreciated, at least one protrusion 80 or more than one protrusion 80 may be included in an upper topography 61C of an access port (not shown) contemplated by the instant disclosure.



FIG. 9 shows another embodiment of a cap 14 including at least one protrusion 80E for forming and identifying an access port contemplated by the instant disclosure after implantation thereof within a patient. Protrusions 80E may extend circumferentially about a center of revolution. Thus, protrusions 80E may exhibit a body 87 portion circumferentially extending between rounded ends 83. Further, cap 14 may have an exterior surface 78 that is substantially symmetric about an axis of revolution. More generally, body 20 may extend from a generally circular, generally elliptical, or generally oval base positioned at a lower extent 71 of the cap 14 to an upper generally circular, generally elliptical, or generally oval cross section that is smaller than a cross section of the base and is positioned at an upper extent 73 (without considering protrusions 80E) of the cap 14. In addition, side surface 51, as shown in FIG. 9, extends arcuately between the base and the upper topography 61 of cap 14. Side surface 51 may extend in a generally tapered or conical fashion, may exhibit a radius or other arcuate shape, or may otherwise transition between a cross section of the base of the access port to a cross section proximate the upper topography 61C thereof.


Further, FIG. 10 shows an embodiment of a cap 14 for forming an access port contemplated by the instant disclosure having an upper topography 61C thereof comprising alternating circumferentially extending protrusions 80E and circumferentially extending recesses 82, wherein the circumferentially extending protrusions 80E are circumferentially larger than the circumferentially extending recesses 80E. In another embodiment of an access port contemplated by the instant disclosure, FIG. 11 shows a perspective view of a cap 14 having an upper topography 61C thereof comprising alternating circumferentially extending protrusions 80E and circumferentially extending recesses 82, wherein the circumferentially extending protrusions 80E and the circumferentially extending recesses 82 are substantially equal in (circumferential) sized or extension. In yet a further embodiment of a cap 14 for forming an access port contemplated by the instant disclosure, FIG. 12 shows a perspective view of a cap 14 having an upper topography 61C thereof comprising three circumferentially extending protrusions 80E and three circumferentially extending recesses 82, arranged so as to alternate circumferentially, wherein the circumferentially extending protrusions 80E and the circumferentially extending recesses 82 are substantially equal in (circumferential) size.



FIG. 13 shows a perspective view of an additional embodiment of an cap 14 for forming an access port contemplated by the instant disclosure including an upper topography 61C including circumferentially extending protrusions 80T and circumferentially extending recesses 82T, wherein transition regions 81 are provided between circumferentially extending protrusions 80T and circumferentially extending recesses 82T. Such transition regions 81, as shown in FIG. 13, may taper or generally smoothly transition between a circumferentially extending protrusion 80T and a circumferentially extending recess 82T. Also, FIG. 14 shows a perspective view of an additional embodiment of a cap 14 for forming an access port contemplated by the instant disclosure including an upper topography 61C including protrusion regions 96 and recessed regions 98 that transition between one another and alternate circumferentially so as to form an undulating topography comprising upper topography 61C. Such an undulating topography, as shown in FIG. 14, generally smoothly transitions between circumferentially adjacent protrusion regions 96 and recessed regions 98.


In a further embodiment of an access port contemplated by the instant disclosure, FIGS. 15A and 15B show a perspective view and a top elevation view, respectively, of an access port 10 generally configured as is described with reference to FIG. 5 but may include at least one nonplanar side surface. In another embodiment, access port 10 as shown in FIG. 15 may be configured as shown in FIGS. 1-4 or FIGS. 6-7, or any embodiments described hereinbelow, without limitation. More specifically, elongated body 20 of access port 10, as shown in FIGS. 15A and 15B, includes three side surfaces 50R that extend arcuately (as shown in FIG. 15B). Such a configuration may provide an access port 10 that is identifiable subsequent to implantation. In yet another embodiment of an access port contemplated by the instant disclosure, FIG. 16 shows a perspective view of an access port 10 including a side wall 100 that truncates a portion of a radius 32 formed between side surfaces 50 of access port 10. It may also be noted that such an access port 10 may include three suture apertures 66, which may, taken alone or in combination with at least one other feature, comprise at least one identifiable feature of an access port contemplated by the instant disclosure. In addition, as shown in FIG. 16, outlet stem 31 may extend from side wall 100.


In a further embodiment of an access port contemplated by the instant disclosure, FIG. 17 shows a perspective view of an access port 10 wherein cap 14 and base 16, when assembled to one another along mating line 15, form a flange feature or lip feature 102 that extends about at least a portion of the periphery of the access port 10. As shown in FIG. 17, lip feature 102 extends substantially about the periphery of the access port 10, proximate to the mating line 15 between cap 14 and base 16. Such a feature may comprise at least one identifiable feature of an access port contemplated by the instant disclosure. Thus, it may be appreciated that a peripheral discontinuity between the cap 14 and base 16 may be formed generally along the mating line 15 therebetween. In the embodiment of an access port as shown in FIG. 7, an overhanging rim feature 76 may comprise a peripheral discontinuity or, in the embodiment of an access port as shown in FIG. 17, a lip feature 102 may comprise a peripheral discontinuity.


In a further embodiment of an access port contemplated by the instant disclosure, FIG. 18 shows a perspective view of an access port 10 wherein at least a portion of at least one side surface 50 is concave. As shown in FIG. 18, concave region 106 of side surface 50 is concave. Concavity (i.e., a concave region 106) may be exhibited over at least a portion of a side surface of an access port of any of the embodiments as shown herein, without limitation. Thus, at least one side surface 50 of an access port contemplated by the instant disclosure having at least at least a portion thereof that is concave is one exemplary example of at least one perceivable feature for identification of an access port contemplated by the instant disclosure.


In a further embodiment of an access port contemplated by the instant disclosure, FIG. 18 shows a perspective view of an access port 10 wherein at least a portion of at least one side surface 50 is concave. As shown in FIG. 18, region 106 of side surface 50 is concave. Concavity may be exhibited over at least a portion of a side surface of an access port of any of the embodiments as shown herein, without limitation. Thus, at least one side surface 50 of an access port contemplated by the instant disclosure having at least at least a portion thereof that is concave is one exemplary example of at least one perceivable feature for identification of an access port contemplated by the instant disclosure.


In a further embodiment of an access port contemplated by the instant disclosure, FIG. 19 shows a perspective view of an access port 10 generally configured as is described with reference to FIGS. 6A and 6B. More specifically, elongated body 20ER, as shown in FIG. 19 includes a side surface 50ER that extends arcuately from upper topography 61 of access port 10 downwardly (i.e., toward reference plane 11 as shown in FIGS. 1A and 1B). Such a configuration may provide an elongated body 20E of an access port 10 having an elongated side portion.


It should be understood from the above-described various embodiments of an access port contemplated by the instant disclosure that many variations, additions, or different features may be encompassed by the instant disclosure. Thus, the instant disclosure is not limited to the several above-described exemplary embodiments.


For example, as shown in FIG. 20, which shows a top elevation view of an access port 10 contemplated by the instant disclosure, an access port 10 may include a side wall 100 that at least partially truncates a radius 32 between side surfaces 50, outlet stem 31 extending from side wall 100, and at least one of a concave region 106 and an arcuate surface 50R. Further, as shown in FIG. 20, suture apertures 66 may be positioned so as to identify the access port 10 after subcutaneous implantation.


Additionally, the instant disclosure contemplates access ports having an exterior geometry that is polygonal in nature. Specifically, the instant disclosure contemplates that an access port contemplated by the instant disclosure may exhibit a generally triangular exterior. Thus, as shown in FIG. 21, body 20 may exhibit a generally pyramidal or tapered shape (i.e., a polygonal base having surfaces for each side of the polygon extending toward a common vertex). Generally, a body 20T of an access port 10 may extend between a generally triangularly-shaped base and a relatively smaller, generally triangularly-shaped upper base. Accordingly, the exterior of access port 10 may be substantially defined by three side surfaces (e.g., 50, 50R, 102, 50E) having radiuses 32 extending therebetween. In addition, the upper topography 61 of access port 10 may be defined by upper surface 60 in combination with side regions 54 and rounded corner regions 30. Such a configuration may provide an access port having at least one feature that may be perceived by palpation.



FIGS. 22 and 23 show a perspective view and a top elevation view of another embodiment of an access port including a generally triangular exterior geometry. More particularly, as shown in FIGS. 22 and 23, a cap 14 and base 16 (collectively forming a housing) may capture a septum 118 to form an access port 10. Further, outlet stem 31 may include a stem base that may be positioned within and sealed to an outlet recess 93 formed within base 16. The outlet stem 31 may be in fluid communication with a cavity formed within the access port 10. Optionally, suture plugs 89 may be positioned within suture cavities 91 formed in base 16. Suture plugs 89 may comprise a pliant material (e.g., silicone, rubber, etc.) that may provide some resilience between sutures coupling the access port 10 (i.e., the base 16) to a patient. In further detail, a side periphery 95 (e.g., one or more side walls) of access port 10 may be generally triangular. Thus, cap 14 and base 16 may collectively form a generally triangular housing or body of access port 10. Also, the instant disclosure contemplates that side periphery 95 may increase or decrease in cross-sectional size (e.g., by tapering or arcuately transforming) between upper surface 161 of cap 14 and lower surface 151 of base 16. As shown in FIGS. 22 and 23, a transverse cross section (taken in a selected plane substantially parallel to lower surface 151 of base 16) of access port 10 may be larger proximate to lower surface 151 of base 16 and may be relatively smaller proximate upper surface 161 of cap 14.


Additionally, FIG. 24 shows a simplified representation of a transverse cross section of access port 10. As shown in FIG. 24, side periphery 95 of access port 10 may define three side regions 103 that extend between associated vertex regions 101. In addition, in one embodiment and as shown in FIG. 24, side periphery 95 may define a substantially equilateral generally triangular shape. As one of ordinary skill in the art will appreciate, side regions 103 may arcuately extend between associated vertex regions 101; thus, side regions 103 may form “sides” of a generally triangular shape. Further, although vertex regions 101 are rounded, it may be appreciated that such vertex regions 101 form an intersection between adjacent side regions 103. Accordingly, one of ordinary skill in the art will appreciate that the phrase “generally triangular,” as used herein, encompasses any generally three-sided geometry wherein adjacent sides intersect, without limitation. For example, the phrase “generally triangular” encompasses three sided polygons, circular triangles, equilateral triangles, etc., without limitation.


The instant disclosure also contemplates that at least one feature of an access port contemplated by the instant disclosure may not be observable visually or by palpation but, rather, may be otherwise observable. For example, the instant disclosure contemplates that at least one feature of an access port may be observable through interaction with an imaging technology such as x-ray or ultrasound. For example, in one embodiment, a metal feature (e.g., a plate or other metal geometry) may be included by an access port contemplated by the instant disclosure. As may be appreciated, such a metal feature may be represented on an x-ray generated by exposure of the access port to x-ray energy while simultaneously exposing x-ray sensitive film to x-ray energy passing through the access port. Further, the instant disclosure contemplates that a size, shape, or both size and shape of a metal feature of an access port may be configured for enhancing identification of an access port. For example, assuming that a metal feature comprises a metal plate, a size, shape, or both may be selectively tailored for identification of an access port. Similarly, a feature of an access port contemplated by the instant disclosure may be tailored for detection via ultrasound interaction. Such a feature may comprise an exterior topographical feature. In another embodiment, such a feature may comprise a composite structure including two or more materials that form an interface surface that may be identified by ultrasound imaging.


One example embodiment of a feature observable through interaction with imaging technology contemplated by the instant disclosure is shown in FIGS. 52, 53A, and 53B. FIG. 52 depicts a bottom perspective view of an access port 10. FIG. 53A shows a top view of the access port 10, while FIG. 53B shows a bottom view of the access port. The access port 10 of FIGS. 52, 53A, and 53B is similar in some respects to the access port 10 as seen in FIGS. 22 and 23, including a cap 14 and a base 16 that cooperate to define a body. In the present example embodiment, however, the lower surface 151 of the base 16 includes an identification feature 200, as seen in FIGS. 52 and 53B. It is contemplated that the identification feature 200 can be one or more alphanumeric characters, such as the “CT” depicted. Additionally, the instant disclosure contemplates the use of other markings, such as one or more symbols, patterns, characters, designs, a combination thereof, etc. The identification feature 200 can be of any size, shape, or both in order to tailor the identification feature for the specific identification of one or more of a variety of characteristics of the access port. Specifically, in one embodiment the identification feature 200 can convey information to a practitioner regarding the power-injectability of the implanted access port. Note that in the present embodiment, the identification feature 200 is defined as a recessed feature, whereas in other embodiments the identification feature may be defined in other ways, as discussed hereafter.


As mentioned above, FIG. 53A depicts a top view of the access port 10. Note that the identification feature 200 is not observable through the upper surface 161 of the cap 14 or through the septum 118 without the interaction of imaging technology. As seen in FIG. 53B, the alphanumeric characters of the identification feature 200, “CT,” are engraved mirror-reversed on the lower surface 151 of the base 16. The “CT” is engraved mirror-reversed so that when imaging technology, such as x-ray imaging, is used to identify a subcutaneously implanted access port, the “CT” will be visible in the proper orientation. By engraving a desired identification feature mirror-reversed on the bottom surface of an access port, a practitioner will be able to determine if there is a problem with the port after implantation, such as if the access port has flipped or otherwise become mis-oriented while in the body of the patient. Thus, if the identification feature is seen mirror-reversed or askew in an x-ray image, the practitioner can correct the problem before attempts are made to use the access port.


Although also useful in access ports where only a portion of a port includes a metallic material, e.g., a metal plate, the engraving technique is well-suited in one embodiment for access ports that are composed of solid metal, such as titanium, stainless steel, or other materials that are typically radiopaque, i.e., non-transmissive to x-rays in sufficient thickness. FIGS. 54A-54C are representative images of the access port 10 of FIG. 52, which includes titanium or other metallic material, as seen via x-ray imaging after implantation into the patient. The access port 10 includes the identification feature 200 as seen in FIGS. 52 and 53B. Due to the relative thickness of the access port 10, the material of the base 16 and cap 14 surrounding a cavity periphery 36A of the cavity 36, which is a fluid cavity, is substantially non-transmissive to x-rays and therefore appears relatively dark in the x-ray image of FIG. 54A. However, the material of the access port 10 within the cavity periphery 36A is relatively thinner through a cavity base 220 (as seen in FIG. 55) than through the material of the cap 14 and base 16. Thus, additional thinning of the material when creating the identification feature 200 enables the identification feature to appear relatively more radiographically transmissive than the surrounding material of the cavity base under x-ray imaging. Note that the identification feature 200 in FIG. 54A is visible in the proper orientation, indicating that the access port is not flipped.



FIGS. 54B and 54C are additional representative x-ray images of the identification feature 200 of the access port 10, wherein the access port is tilted at angles of approximately 20 and 50 degrees, respectively. Thus, the identification feature 200 is also useful for determining relative orientation of the access port 10 after implantation.



FIG. 55 shows a cross-sectional view taken at line 55-55 of the access port 10 in FIG. 52. In this example embodiment, the identification feature 200 is disposed beneath the septum 118 and the cavity 36. FIGS. 56A and 56B further depict enlarged cross-sectional views of potential cut profiles of the recessed identification feature 200. FIG. 56A shows a rounded engraving profile 201, engraved on the lower surface 151 of the base 16 and used for purposes of aesthetics and ease of manufacturing. For a relatively more defined contrast under imaging technology, however, a sharp-edged engraving profile 202 may be used, as seen in FIG. 56B. Note that a variety of cross-sectional recessed profiles may be employed. This disclosure further contemplates that although engraving is discussed here, other methods of marking the identification feature may be used, such as milling, machining, chemical or laser etching, molding, stamping, etc.


Regardless of the cut profile used, better contrast is achieved generally with greater engraving depth X. The optimal engraving depth X will depend, however, on the thickness of the overall cavity base 220, which is the portion of the base directly below the cavity 36, as shown in FIG. 55. For example, in an embodiment of an access port including titanium, if the overall thickness of the cavity base 220 is approximately 0.020″ then sufficient contrast for x-ray imaging purposes can be obtained in one embodiment by engraving the identification feature 200 to a depth X (FIGS. 56A, 56B) of between about 0.009″ and about 0.011″. In another example embodiment of an access port including titanium, where the overall thickness of the cavity base 220 is approximately 0.030″, sufficient contrast can be obtained by engraving the identification feature 200 to a depth X of between about 0.015″ and about 0.021″. One of ordinary skill in the art will appreciate that the depth of an engraved identification feature can be varied substantially in order to comply with a product's safety requirements and still remain within the scope contemplated by this disclosure. In addition, the depth X of the identification feature can vary according to the position of the feature on the access port, the thickness of material to be penetrated by the imaging technology, the type of material included in the access port, etc.


It is also contemplated by this disclosure that the use of an identification feature in a metallic or other radiopaque access port can be applied to access ports having a variety of possible configurations, such as is seen in FIGS. 57A-58C, for example. FIGS. 57A-57C depict one embodiment, wherein the access port 10 includes an identification feature 200 on a lower surface 251 of a base or body 116. The access port 10 in FIGS. 57A-57C includes a retaining ring 230, which seals the septum 118 to the base or body 116, over the cavity 36. In one embodiment, the retaining ring 230 is press fit into the base or body 116 to hold the septum 118 in place. FIGS. 58A-58C show yet another embodiment, wherein the access port 10 includes an identification feature 200 on the cavity base 220 and wherein the cavity base is mated to and flush with a lower surface 252 of a cap 114 to define a body. In a particular embodiment, the cavity base 220 is press fit into the cap 114, though other mating configurations can also be employed.


In another embodiment contemplated by the instant disclosure, FIGS. 59A and 59B show that the location of the identification feature 200 can vary as well. Rather than placing the identification feature 200 under the cavity 36, it is possible to place the identification feature under another portion of the access port 10, such as under the outlet stem 31 and between the septum plugs 89, i.e., proximate the outer periphery of the access port bottom surface. Though the overall thickness of the access port structure above the identification feature 200 is greater in this location than if engraved under the cavity 36, the change in location allows for a relatively deeper engraving, which will increase contrast without risk of excessive thinning of the cavity base 220. Additionally, in one embodiment, it is possible to define the identification feature compositely by engraving into both the bottom and top surfaces, such that the engravings are vertically aligned. This enables the remaining material thickness to be substantially reduced in order to provide relatively greater radiographic transmission through the identification feature.


Additionally, the instant disclosure contemplates access ports having any variety or combination of desired identification features for indicating power-injectability or other aspect or characteristic of an access port. Specifically, FIGS. 60A-61B depict different types of identification features 200, according to example embodiments. FIGS. 60A-60B depict a symbolic identification feature 200. FIGS. 61A-61B depict an exemplary embodiment of an access port 10 including a combination of identification features 200, namely an alphanumeric identification feature 200A and a patterned identification feature 200B. A patterned or symbolic identification feature can also be used to help indicate the orientation of the port or for any other desired reason. It is understood by the instant disclosure that other symbols, patterns, marks, and alphanumeric characters can be used both alone and in any combination with each other on a variety of access port configurations.


In additional embodiments, the identification feature can be defined on an inside bottom surface 36B of the cavity 36 of an access port 10, or in addition to the identification feature 200 provided on the bottom surface 251. In another embodiment, the material surrounding the defining edges of the desired radiopaque alphanumeric character, symbol, pattern, etc., can be removed instead of removing the desired feature shape itself so as to define a “positive” relief image of the identification feature. Such a positive relief identification feature can be defined on a lower surface of an access port body or on the inside bottom surface of the cavity, for example.


In addition to the various types of symbols, patterns, marks, and alphanumeric characters that are contemplated by the instant disclosure, FIGS. 62A-63C disclose additional example embodiments of identifying features on access ports that are observable via x-ray or other suitable imaging technology. Specifically, the instant disclosure contemplates the use of shelled-out cavities 204, wherein portions of the access port 10 are hollowed out. This results in shelled-out cavities 204 extending inward from the lower surface 251 of the base or body 116 or corresponding port lower surfaces of the other embodiments described herein, including the lower surface 151 of the base 16, as in FIG. 151, and the lower surface 252 of a cap 114, as in FIGS. 58A-58C. This is done by removing the material surrounding the cavity 36 without disrupting the cavity periphery 36A or the outer side surfaces 250 of the access port 10. As seen in FIG. 62B, ribs 240 may be left to support the remaining “shelled” frame of the access port 10. The definition of such cavities 204 provides a relative difference in radiopacity of the access port 10 that can be identified via x-ray imaging. As such, the cavities 204 can be arranged to define a pattern or to form an indicia for identification of an aspect or characteristic of the access port 10. Note that in other embodiments, the cavities can be defined so as to extend from other surfaces of the access port, including the top and sides thereof.


In a further aspect contemplated by the instant disclosure, it is contemplated that a communicative technology may be utilized wherein information is encompassed by an access port contemplated by the instant disclosure. Generally, a communication device (e.g., a radio beacon, a light-emitting element, an ultrasound emitting transducer, etc.), may be imbedded or otherwise affixed to an access port contemplated by the instant disclosure. Such a communication device may be configured for transmitting information in response to a given impetus. More specifically, the instant disclosure contemplates that an access port contemplated by the instant disclosure may be exposed to a request signal (e.g., a sound, an impact or an acceleration, light, radio waves, etc.). Such a request signal may cause the communication device to transmit information therefrom via sound, light, radio waves, or as otherwise known in the art. Such information may be employed for identifying an access port contemplated by the instant disclosure.


In one exemplary example, it is contemplated that radio frequency identification technology may be employed for identification of an access port contemplated by the instant disclosure. Particularly, so-called active RFID tags are powered by an internal battery and are typically read/write devices. Currently, a suitable cell coupled to suitable low power circuitry can ensure functionality for as long as ten or more years, depending upon the operating temperatures and read/write cycles and usage. So-called passive RFID tags operate without a separate external power source and obtain operating power generated from the reader. Passive RFID tags are typically programmed with a unique set of data (usually 32 to 128 bits) that cannot be modified. Read-only tags may operate as an identifier comparable to linear barcodes which may contain selected product-specific information. Thus, passive RFID tags may be much lighter than active RFID tags, less expensive, and may offer a virtually unlimited operational lifetime. The tradeoff is that they have shorter read ranges than active tags and require a higher-powered reader.


One advantage of RFID approach is the noncontact, non-line-of-sight nature of the technology. Tags can be read through a variety of substances such as snow, fog, ice, paint, crusted grime, and other visually and environmentally challenging conditions, where other optically read technologies may be less effective. RFID tags can also be read in challenging circumstances at rapid speeds, in most cases responding in less than about 100 milliseconds.


Reference is now generally made to FIGS. 64-75C in describing additional embodiments wherein an access port includes at least one identification feature observable through interaction with an imaging technology, such as x-ray and fluoroscopy, for instance, in order to facilitate identification of at least one attribute, or characteristic, of an access port subsequent to implantation within the body of a patient. It is appreciated that the embodiments to be described can be included alone or together with other identification features described herein and may be employed with access ports having a variety of sizes, shapes, and other variations in configuration. As such, the embodiments described herein are merely examples of the principles of the present disclosure.



FIG. 64 shows an access port 310 including a base 316 and a septum 318 covering a reservoir defined by the base. The septum 318 includes a plurality of palpation bumps 320 for enabling external digital palpation and location of the septum by a clinician after the access port 310 has been subcutaneously implanted. The port 310 includes a retaining ring 330 for capturing and retaining the septum 318 in place atop the port reservoir. In the present embodiment, both the port base 316 and the retaining ring are metallic substance, including titanium for instance, though in other embodiments other suitable materials may be used.


In the present embodiment the retaining ring 330 includes an identification feature 200 for identifying a predetermined attribute or characteristic of the port 310 after implantation thereof. Specifically, the retaining ring 330 includes alphanumeric character identification features 200A spelling “POWER INJECTABLE,” which indicates that the port 310 is capable of power injection. The alphanumeric characters in one embodiment are inset via etching or otherwise suitably defined in the retaining ring 330 so as to provide a relative thickness difference between the characters and surrounding metallic retaining ring material, thus providing a corresponding radiographic contrast when the port 310 is imaged with x-ray imaging technology. This contrast enables the alphanumeric characters to become visible in an x-ray and therefore discernible by a clinician viewing the x-ray, thus enabling the port attribute or characteristic relating to the identification feature 200 to be ascertained.


Note that the alphanumeric identification features 200A can be defined on the retaining ring 330 in any number of suitable ways, including etching, engraving, etc., and the characters can be defined partially or completely through the retaining ring. Also, the particular characters or words used can vary from what is described here. Indeed, other characters, patterns, symbols, etc. can be employed in the identification feature 200. Optionally, the identification features can be defined in negative relief, as shown in FIG. 64, or in positive relief, if desired.


Additionally, in other embodiments the identification feature of the retaining ring can be configured in other ways according to the configuration of the port. For instance, in embodiments where the port body includes a non-metallic material, the identification feature can include radiopaque ink that is applied to a surface of the retaining ring so as to form the alphanumeric or other characters or features. In yet other embodiments, the identification feature can be included on portions or surfaces of the port in addition to the retaining ring. These and other modifications are therefore contemplated.



FIG. 65 includes the metallic retaining ring 330 of the metallic port 310 configured in accordance with another embodiment, wherein the retaining ring defines the identification feature 200, including a plurality of overlapping portions 330A that each overlap a portion of the septum 318 retained by the retaining ring. In FIG. 65, the overlapping portions 330A of the retaining ring 330 cooperate to generally define a triangular shape, which provides a radiographic contrast relative to portions of the metallic port 310 below the retaining ring. As before, this provides a corresponding radiographic contrast when the port 310 is imaged with x-ray imaging technology, enabling the triangular shape to be discernible as a radiopaque outline by a clinician viewing the x-ray in order to ascertain the predetermined port attribute or characteristic relating to the identification feature 200 to be ascertained. In other embodiments, the retaining ring can define other shapes in addition to the triangular shape shown here. Additionally, characters, symbols, or other patterns can be defined in or included on the overlapping portions of the retaining ring if desired.



FIGS. 66A-66D depict various details regarding the inclusion of an identification feature for identifying a predetermined attribute or characteristic of an access port after implantation into a patient. Specifically, these figures depict a dual reservoir access port 410, including a cap 414 matable to a base 416 and two septa 418 interposed between the cap and base. Suture plugs 422 are included with the port 410. In accordance with the present embodiment, a bottom surface 416A of the port base 416 includes the identification feature 200 for identification of the subcutaneously implanted port. As best seen in FIG. 66B, the identification feature 200 in the present embodiment includes a radiopaque marking including the letters “C” and “T” outlined by a double-triangle border, though many different character, pattern, and/or combination configurations are possible. For instance, in addition to identifying the access port as power injectable, this and other identification features described herein can be used to designate lot numbers, hospital identification, port brand, etc.


The radiopaque marking of the identification feature 200 can include a metallic powder intermixed with an ink-based marking. Specifically, in one embodiment, the radiopaque marking includes tungsten powder intermixed with 1020 black wire marking ink manufactured by Gem Gravure, Inc. of West Hanover, Mass., in a ratio of three parts tungsten powder to one part ink. Mixing of the two components can include ball mixing to ensure good component integration in one embodiment. Also, additives can be added to the mixture to attain a proper mixture viscosity.


In other embodiments, the powder-to-ink ratio can be modified from that described above, including 2:1, 4:1, and 5:1 ratios, for instance. The ideal ratio will vary according to the type of materials employed in the mixture, the density of the desired image, powder particle size, amount of mixture applied to the port, etc. In yet other embodiments, other medical grade inks or suitable liquids, as well as other biocompatible metallic powders or suitable radiopaque materials, could be used. In one embodiment, a ceramic, such as zirconium oxide powder, can be intermixed with a marking ink to provide the radiopaque marking. Ink thinners can also be added to the mixture, along with other suitable substances as appreciated by those skilled in the art.


As shown in FIG. 66B, the ink-based radiopaque marking that forms the identification feature 200 in the present embodiment is included on a substrate 440. In one embodiment, the substrate 440 includes a material substantially identical to the material included in the port 410. Specifically, in one embodiment, both the port 410 and the substrate 440 include an acetyl resin sold under the brand DELRIN®, though it is appreciated that other suitable materials could be used for the substrate and port.


The substrate 440 is employed as a base on which the radiopaque marking can be deposited in preparation for integration of the substrate and marking into the port 410 during an injection molding process so as to encapsulate the radiopaque marking within the molded port. In detail, in one embodiment, the radiopaque marking, including the above-described ink/powder mixture or other suitable substance, is first deposited on a surface of the substrate 440 via any acceptable process, including pad printing, manual or automatic painting, silk screening, use of a template, etc. To improve adhesion of the ink/powder mixture, the substrate can be plasma treated or corona treated in one embodiment.


Once the radiopaque marking has been applied to the substrate 440, the substrate is loaded into a mold, such as that shown in FIG. 66C, which depicts the substrate positioned within a cavity 444 of a portion of a mold 442. The substrate 440 is positioned within the mold cavity 446 such that the radiopaque marking is facing in toward what will become the center of the port 410. In one embodiment, the substrate 440 is held in place within the mold cavity 444 via a vacuum assist system; in other embodiments, temporary mechanical fixation can be employed, if necessary. A template including a hole sized to enable the substrate to pass therethrough can be used in one embodiment to assist the technician in placing the substrate 440 with the proper orientation within the mold cavity 444.


The port 410 is then fabricated by an injection molding process. The substrate 440 is thus insert-molded into the port 410 via the injection molding process, which bonds the substrate 440 to the molded body of the port 410, thus encapsulating the radiopaque marking of the identification feature 200 within the port and preventing its inadvertent removal. Additionally, due to the relative thinness of the substrate 440, the identification feature remains visible through the substrate from outside of the port 410, as seen in FIG. 66D, before implantation. In one embodiment, the thickness of the substrate 440 ranges from about 0.002 inch to about 0.015 inch, though other thicknesses can be acceptably used. Later, when the port 410 is implanted and imaged under x-ray, the identification feature 200 will be visible in the x-ray image and useful to identify an attribute or characteristic of the implanted port.


It is appreciated that in other embodiments, the substrate can be configured to be positioned in other regions of the port. In yet other embodiments, other substrate materials can be used. For instance, in one embodiment the substrate can include woven high-density polyethylene sold under the brand TYVEK®. In this case, the substrate 440 does not permanently adhere to the port 410 as a result of the insert molding process, but is removed after molding process is complete. The radiopaque marking ink/powder mixture initially included on the woven substrate 440, however, is integrated into the port body and remains with the port 410 after molding and substrate removal to serve as the identification feature 200. Flaps or flanges can be included on the substrate to facilitate its separation from the substrate from the port after molding, in one embodiment. In another embodiment, the ink/powder radiopaque marker mixture is allowed to dry on the substrate 440 after application thereon to improve adhesion to the port 410 during the insert molding process. In addition to those explicitly described here, other suitable materials can be used as the substrate. In yet another embodiment, no substrate is used and the ink/powder radiopaque marker mixture is applied directly to the mold surface before the port 410 is molded therein.



FIGS. 74A and 74B depict details of the substrate 440 and identification feature 200 configured in accordance with another embodiment, wherein the substrate forms a portion of the port base. A raised surface 440A is included on the substrate, and a radiopaque marking, such as the intermixed marking ink and radiopaque powder, is included on the raised surface to define the identification feature 200. Application of the radiopaque marking can occur in any one of a number of suitable ways, including contact application by a stamp or tamp pad, ink jet printing, physical or chemical deposition, etc.


The substrate 440 with the included identification feature 200 can then be inserted into a mold and insert-molded to form part of a base 616 of an access port. The radiopaque identification feature 200, now encapsulated within the base, provides the desired identification of a predetermined attribute or characteristic of the port once manufacture of the port is complete.


Reference is now made to FIG. 67, which depicts another identification feature for an access port, such as a plastic port for instance, according to one embodiment. In particular, the port 410 of FIG. 67 includes a cavity 446 defined on a bottom surface 416A of the port base 416. In one embodiment, the cavity 446 is defined to a depth of about 0.010 inch, though other depths can also be used according to desire and port configuration. The cavity 446 is filled with a radiopaque fill material 448. The cavity 446 is shaped with a predetermined design or configuration so as to form the identification feature 200 when filled with the radiopaque fill material 448, thus enabling a predetermined attribute or characteristic of the port 410 to be identified via x-ray imaging subsequent to implantation. In the present embodiment, the fill material 448 includes tungsten powder intermixed with a two-part silicone sold under the brand SILASTIC® Q7-4840, available from Dow Corning Corporation, Midland, Mich. in equal quantities, i.e., equal parts of part A silicone, part B silicone, and tungsten powder. Of course, other suitable materials could also be employed. For instance, titanium can be used in place of tungsten, and biocompatible urethane adhesives can be used in place of silicone.


In one embodiment, the fill material 448 is injected into the cavity 446 by a pressurized syringe, such as an electronic fluid dispenser, though other suitable techniques can also be employed, including manual filling by syringe. Any excess fill material 448 can be removed from the port base bottom surface 416A after filling, and the fill material can be allowed to cure. Note that in other embodiments the bottom surface of the port can include other portions of the port in addition or instead of the base, as shown in FIG. 67.



FIGS. 68A-68C show details of one embodiment for providing the identification feature 200 on a resilient septum 468 of an implantable access port, such as a plastic port for instance, wherein the septum includes a radiopaque portion visible under x-ray imaging to provide information relating to an attribute or characteristic of the septum itself and/or the access port in which the septum is disposed. In the illustrated embodiment, the radiopaque portion is defined as an annular portion 470 disposed about the upper outer periphery of the septum 468 so as not to interfere with puncturing of the septum by needles during port use. As best seen in FIG. 68C, the annular portion does not extend in depth through the thickness of the septum outer portion, but in other embodiments the thickness, size, and position of the radiopaque portion can vary on the septum.


In the present embodiment, the radiopaque annular portion 470 includes barium sulfate-loaded silicone, while the remainder of the septum 468 is unloaded silicone. In other embodiments, other suitable radiopaque materials can be employed with silicone or other septum materials. In one embodiment, the septum 468 of FIGS. 68A-68C can be formed by a two-part molding process, wherein the annular portion 470 is manufactured separately from the rest of the septum 468, then the two parts are adhered together by a suitable adhesive, mechanical fixation, etc., to form the structure shown in FIGS. 68A-68C.


In another embodiment, the present septum 468 is manufactured integrally via a co-molding process, wherein separate injection heads are employed in a mold cavity in order to injection mold the annular portion 470 with one or more heads and the rest of the septum 468 with separate heads. These and other manufacturing methods are therefore considered within the spirit of the present disclosure.


The principles discussed in connection with FIGS. 68A-68C can be expanded in one embodiment shown in FIG. 69, wherein a port 510 including resilient suture plugs 522 disposed in corresponding suture plug holes 524 is configured such that the suture plugs include a radiopaque material, such as the barium sulfate-loaded silicone employed in the septum 468 of FIGS. 68A-68C or other suitable radiopaque material. So configured, the suture plugs provide the identification feature 200 that is visible under x-ray imaging to provide information relating to an attribute or characteristic of the port 510. In one embodiment, the port 510 can include both the radiopaque suture plugs 522 and the septum 468 including the radiopaque portion 470 in order to provide additional identification ability and/or to provide information relating to the orientation of the port within the body of the patient. In addition to barium sulfate, the suture plugs can include tungsten, tantalum, or other suitable radiopaque materials. In yet another embodiment, one or more radiopaque beads can be disposed in the port body to provide similar port visibility under x-ray.


In one embodiment, the septum, suture plugs, or other portion of the port can include an ultraviolet light-sensitive material. The ultraviolet light-sensitive material can be applied to the surface of the port component or can impregnated into the component. After implantation of the port, ultraviolet light is directed through the skin of the patient to be incident on the ultraviolet light-sensitive material of the port, which causes the material to fluoresce with visible light that is observable through the skin of the patient, thus identifying the port and/or its predetermined attribute or characteristic.


It is appreciated that a radiopaque identification feature can be included or associated with a port in other ways in addition to those embodiments already described. Examples of this can be found in the embodiments depicted in FIGS. 70-72. In FIG. 70, for example, an identifier tag 550 is shown, including a ring portion 552 with a slit 554 for enabling the identifier ring to be attached to a catheter that is operably attached to the stem of a port. The identifier tag 550 further includes a face portion 556 on which a radiopaque identification feature 200 can be placed for visibility via x-ray imaging to identify a predetermined attribute or characteristic of the port. The tag can be designed in various different shapes and configurations. For instance, the tag can be included as part of a catheter securement device for locking an end of a catheter to the stem of the port.


In FIG. 71, the port 510 is shown with a catheter securement device 540 that is used to secure the connection between an end of a catheter 512 and a stem 530 of the port. A body 542 of the catheter securement device 540 is configured to include the identification feature 200 for visibility via x-ray imaging to identify a predetermined attribute or characteristic of the port to which the device is attached. Again, the shape, size, and particular configuration of the catheter securement device and identification feature can vary from what is shown and described herein.


In FIG. 72, the port 510 is shown with the catheter 512 operably attached thereto. The catheter 512 includes two flaps 550 that extend from the body thereof, on which the identification feature 200 is included in order to provide a visible identification of a predetermined attribute or characteristic of the catheter and/or port when imaged under x-ray. Of course, the particular identification feature, as well as the number and size/configuration of the catheter flaps can vary from what is described herein.



FIGS. 73A and 73B depict yet another example of a radiopaque identification feature wherein the identification feature 200 is included in an insert 570 formed from a radiopaque material, such as tungsten or other suitable material. The insert 570 is suitable for placement in a plastic or other radiotranslucent port such that the insert is visible under x-ray imaging to identify an attribute or characteristic of the port. Orientation arrows 572 provide useful indicia of the orientation of the port. By examining the direction of the arrows 572, a clinician observing an x-ray image of the port insert 570 can determine whether the port is flipped in the body of the patient. In addition to these, other indicia indicating port orientation can be included on the insert in other embodiments.



FIGS. 75A-75C show implementation of another example of a radiopaque insert, in addition to that shown in FIGS. 73A and 73B, which is included to serve as the identification feature 200 for identifying a predetermined attribute or characteristic of a port, including a plastic port, as in the present embodiment. In particular, a radiopaque insert 670 is shown, configured to be interposed between a cap 714 and a base 716 of a port 710. Note that, though the insert 670 shown here is configured to fit over a dual fluid cavity 712 of the port 710, other inserts including a variety of radiopaque compositions can be configured to be included in other ways with a port. Additionally, the port can define one, two, or more fluid cavities covered by septa 718, without limitation.


As shown in FIG. 75B, the insert 670 fits over the fluid cavities 712 of the port 710 so as to rest on a portion of the port base 716. So positioned, the insert 670 is sandwiched and secured between the base 716 and the cap 714 when the base and cap are mated together to form the port 710. Such mating can be accomplished by ultrasonic welding, adhesives, etc. The resulting interposition of the insert 670 between the base 716 and cap 714 is shown in FIG. 75C. When the port 710 is later imaged via x-ray after patient implantation, the insert 670 is readily visible, thus enabling the predetermined attribute/characteristic(s) of the port to be identified.


While certain representative embodiments and details have been shown for purposes of illustrating aspects contemplated by the instant disclosure, it will be apparent to those skilled in the art that various changes in the methods and apparatus disclosed herein may be made without departing form the scope contemplated by the instant disclosure, which is defined in the appended claims. For example, other access port sizes and shapes may be employed; and various other embodiments and structures may be employed for forming at least one identifiable feature of an access port contemplated by the instant disclosure. In particular, FIGS. 25-51 illustrate a number of additional exemplary embodiments of access port 10. As is apparent from these figures, access port 10 may be formed in any number of shapes and sizes, such that any number of modifications and changes are possible to any of the embodiments described and illustrated herein without departing from the spirit and scope of the instant disclosure.

Claims
  • 1. An access port for providing subcutaneous access to a patient, comprising: a port base defining a fluid cavity, the port base formed from a base material;a substrate separate from the port base formed from a substrate material, the substrate attached to the port base, the substrate including an inner surface facing toward the fluid cavity and an outer surface facing away from the fluid cavity; anda radiopaque material adhered to the substrate inner surface prior to attachment of the substrate to the port base, the radiopaque material including an identification feature.
  • 2. The access port as defined in claim 1, wherein the substrate material includes an acetyl resin or a high-density polyethylene.
  • 3. The access port as defined in claim 1, wherein the substrate material and the base material are substantially similar.
  • 4. The access port as defined in claim 1, wherein the identification feature is visible through the substrate after attachment of the substrate to the port base.
  • 5. The access port as defined in claim 1, wherein the substrate is insert molded with the port base, and wherein the radiopaque material includes a metallic powder intermixed with an ink.
  • 6. The access port as defined in claim 5, wherein the metallic powder is tungsten powder and wherein the tungsten powder is intermixed with the ink at a ratio of three parts tungsten powder to one part ink.
  • 7. The access port as defined in claim 1, wherein the identification feature includes the letters “C” and “T”.
  • 8. The access port as defined in claim 7, wherein the letters are outlined by a double-triangle border.
  • 9. The access port as defined in claim 1, wherein the identification feature identifies the access port as power injectable.
  • 10. The access port as defined in claim 9, wherein the identification feature further identifies one or more of: the access port lot number, a hospital identification, and the access port brand.
  • 11. The access port as defined in claim 1, wherein the substrate material comprises a woven material, and wherein the port base is insert molded over the substrate.
  • 12. The access port as defined in claim 11, wherein the substrate is removed after the molding process is complete.
  • 13. The access port as defined in claim 12, wherein the substrate includes flaps or flanges extending from the outer perimeter to facilitate separation of the substrate from the port.
  • 14. A power injectable access port, comprising: a port base defining a fluid cavity, the port base formed from a base material;a substrate separate from the port base formed from a substrate material, the substrate material being the same as the base materiala radiopaque material deposited on a surface of the substrate, the radiopaque material including a feature identifying the access port as power injectable,wherein the substrate is coupled to the port base such that: the radiopaque material is encapsulated between the substrate material and the base material; andthe feature identifying the access port as power injectable is visible through the substrate prior to implantation.
  • 15. The power injectable access port as defined in claim 14, further comprising a port cap positioned over the port base to capture a septum therebetween.
  • 16. The power injectable access port as defined in claim 14, wherein the radiopaque material comprises a metallic powder intermixed with a marking ink.
  • 17. The power injectable access port as defined in claim 14, wherein the radiopaque material is included on a raised surface of the substrate.
  • 18. The power injectable access port as defined in claim 14, wherein the radiopaque material is deposited on the surface of the substrate via a process selected from the group consisting of pad printing, manual painting, automatic painting, and silk screening.
  • 19. The power injectable access port as defined in claim 14, wherein the substrate has a thickness in the range from about 0.002 inch to about 01015 inch.
RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No. 12/610,084, filed Oct. 30, 2009, now U.S. Pat. No. 8,202,259, which claims the benefit of U.S. Patent Application No. 61/110,507, filed Oct. 31, 2008 and which is a continuation-in-part of U.S. patent application Ser. No. 12/420,028, filed Apr. 7, 2009, now U.S. Pat. No. 7,947,022, which is a continuation-in-part of U.S. patent application Ser. No. 11/368,954, filed Mar. 6, 2006, now U.S. Pat. No. 7,785,302, which claims the benefit of U.S. Patent Application No. 60/658,518, filed Mar. 4, 2005. Each of the afore-referenced applications is incorporated, in its entirety, by this reference.

US Referenced Citations (733)
Number Name Date Kind
445896 Kinsman Feb 1891 A
546440 Tufts Sep 1895 A
574387 Buckler Jan 1897 A
611357 Dembinski Sep 1898 A
966696 Merrill Aug 1910 A
1713267 Crowley May 1929 A
2029553 Bartischi et al. Feb 1936 A
2433480 Rendich Dec 1947 A
2891689 Gould Jun 1959 A
D198453 Weichselbaum Jun 1964 S
3159175 Macmillan Dec 1964 A
3293663 Cronin Dec 1966 A
3341417 Sinaiko Sep 1967 A
3477438 Allen et al. Nov 1969 A
3518428 Ring Jun 1970 A
3525357 Koreski Aug 1970 A
3529633 Vailancourt Sep 1970 A
3540670 Rissberger Nov 1970 A
3541438 Nelsen et al. Nov 1970 A
3643358 Morderosian Feb 1972 A
3669323 Harker et al. Jun 1972 A
3674183 Venable et al. Jul 1972 A
3811466 Ohringer May 1974 A
3829904 Ling et al. Aug 1974 A
3831549 Parsons Aug 1974 A
3831583 Edmunds, Jr. et al. Aug 1974 A
3840009 Michaels et al. Oct 1974 A
3853127 Spademan Dec 1974 A
3891997 Herbert Jul 1975 A
3915162 Miller Oct 1975 A
3919724 Sanders et al. Nov 1975 A
3922726 Trentani et al. Dec 1975 A
3951147 Tucker et al. Apr 1976 A
3955594 Snow May 1976 A
3971376 Wichterle Jul 1976 A
4027391 Samis Jun 1977 A
4035653 Karasko Jul 1977 A
4121108 Manor Oct 1978 A
4123806 Amstutz et al. Nov 1978 A
4143853 Abramson Mar 1979 A
4168586 Samis Sep 1979 A
4181132 Parks Jan 1980 A
4190040 Schulte Feb 1980 A
4190057 Hill et al. Feb 1980 A
4194122 Mitchell et al. Mar 1980 A
4196731 Laurin et al. Apr 1980 A
4202349 Jones May 1980 A
4222374 Sampson et al. Sep 1980 A
4233964 Jefferts et al. Nov 1980 A
4274006 Caine Jun 1981 A
4349498 Ellis et al. Sep 1982 A
4361153 Slocum et al. Nov 1982 A
4405305 Stephen et al. Sep 1983 A
4406567 Samis Sep 1983 A
4425119 Berglund Jan 1984 A
4445896 Gianturco May 1984 A
4447237 Frisch et al. May 1984 A
4450592 Niederer et al. May 1984 A
4450985 Beard May 1984 A
4456011 Warnecke Jun 1984 A
4469483 Becker et al. Sep 1984 A
4479798 Parks Oct 1984 A
4494545 Slocum et al. Jan 1985 A
4506676 Duska Mar 1985 A
4529635 Sheldon Jul 1985 A
4543088 Bootman et al. Sep 1985 A
4549879 Groshong et al. Oct 1985 A
4559046 Groshong et al. Dec 1985 A
4560375 Schulte et al. Dec 1985 A
4569675 Prosl et al. Feb 1986 A
4571749 Fischell Feb 1986 A
4576595 Aas et al. Mar 1986 A
4610665 Matsumoto et al. Sep 1986 A
4612877 Hayes et al. Sep 1986 A
4626244 Reinicke Dec 1986 A
4627844 Schmitt Dec 1986 A
4634427 Hannula et al. Jan 1987 A
4636194 Schulte et al. Jan 1987 A
4636213 Pakiam Jan 1987 A
4645495 Vaillancourt Feb 1987 A
4653508 Cosman Mar 1987 A
4655765 Swift Apr 1987 A
4657024 Coneys Apr 1987 A
4662652 Hargis May 1987 A
4668221 Luther May 1987 A
4671796 Groshong et al. Jun 1987 A
4673394 Fenton, Jr. et al. Jun 1987 A
4684365 Reinicke Aug 1987 A
4685447 Iversen et al. Aug 1987 A
4685905 Jeanneret nee Aab Aug 1987 A
4692146 Hilger Sep 1987 A
4695273 Brown Sep 1987 A
4697595 Breyer et al. Oct 1987 A
4701166 Groshong et al. Oct 1987 A
4704103 Stober et al. Nov 1987 A
4707389 Ward Nov 1987 A
4710174 Moden et al. Dec 1987 A
4718894 Lazorthes Jan 1988 A
4723947 Konopka Feb 1988 A
4728894 Yoda et al. Mar 1988 A
4743231 Kay et al. May 1988 A
4753640 Nichols et al. Jun 1988 A
4755173 Konopka et al. Jul 1988 A
4760837 Petit Aug 1988 A
4762517 McIntyre et al. Aug 1988 A
4767410 Moden et al. Aug 1988 A
4772270 Wiita et al. Sep 1988 A
4772276 Wiita et al. Sep 1988 A
4773552 Boege et al. Sep 1988 A
4778452 Moden et al. Oct 1988 A
4781680 Redmond et al. Nov 1988 A
4781685 Lehmann et al. Nov 1988 A
4781695 Dalton Nov 1988 A
4784646 Feingold Nov 1988 A
4802885 Weeks et al. Feb 1989 A
4804054 Howson et al. Feb 1989 A
4820273 Reinicke Apr 1989 A
4822341 Colone Apr 1989 A
4840615 Hancock et al. Jun 1989 A
4848346 Crawford Jul 1989 A
4857053 Dalton Aug 1989 A
4861341 Woodburn Aug 1989 A
4863470 Carter Sep 1989 A
4886501 Johnston et al. Dec 1989 A
4886502 Poirier et al. Dec 1989 A
4892518 Cupp et al. Jan 1990 A
4897081 Poirier et al. Jan 1990 A
4904241 Bark Feb 1990 A
4905709 Bieganski et al. Mar 1990 A
4908029 Bark et al. Mar 1990 A
4909250 Smith Mar 1990 A
4915690 Cone et al. Apr 1990 A
4928298 Tanaka May 1990 A
4929236 Sampson May 1990 A
4955861 Enegren et al. Sep 1990 A
4961267 Herzog Oct 1990 A
4963133 Whipple Oct 1990 A
4966583 Debbas Oct 1990 A
4973319 Melsky Nov 1990 A
4983162 Metais et al. Jan 1991 A
5002735 Alberhasky et al. Mar 1991 A
5009391 Steigerwald Apr 1991 A
5009644 McDonald Apr 1991 A
5013298 Moden et al. May 1991 A
5041098 Loiterman et al. Aug 1991 A
5044955 Jagmin Sep 1991 A
5045060 Melsky et al. Sep 1991 A
5045064 Idriss Sep 1991 A
5053013 Ensminger et al. Oct 1991 A
5059186 Yamamoto et al. Oct 1991 A
5069206 Crosbie Dec 1991 A
5084015 Moriuchi Jan 1992 A
5085216 Henley, Jr. et al. Feb 1992 A
5090066 Schoepe et al. Feb 1992 A
5092849 Sampson Mar 1992 A
5108317 Beinhaur et al. Apr 1992 A
5108377 Cone et al. Apr 1992 A
5112301 Fenton, Jr. et al. May 1992 A
5112303 Pudenz et al. May 1992 A
5129891 Young Jul 1992 A
5137529 Watson et al. Aug 1992 A
5147483 Melsky et al. Sep 1992 A
5152753 Laguette et al. Oct 1992 A
5156600 Young Oct 1992 A
5158547 Doan et al. Oct 1992 A
5167629 Vertenstein et al. Dec 1992 A
5167633 Mann et al. Dec 1992 A
5167638 Felix et al. Dec 1992 A
5169393 Moorehead et al. Dec 1992 A
5171228 McDonald Dec 1992 A
5176653 Metals Jan 1993 A
5176662 Bartholomew et al. Jan 1993 A
5178612 Fenton, Jr. Jan 1993 A
5185003 Brethauer Feb 1993 A
5189690 Samuel Feb 1993 A
5193106 DeSena Mar 1993 A
5195122 Fabian Mar 1993 A
5195123 Clement Mar 1993 A
5201715 Masters Apr 1993 A
5201722 Moorehead et al. Apr 1993 A
5203771 Melker et al. Apr 1993 A
5203777 Lee Apr 1993 A
5205834 Moorehead et al. Apr 1993 A
5213574 Tucker May 1993 A
5215537 Lynn et al. Jun 1993 A
5222499 Allen et al. Jun 1993 A
D337637 Tucker Jul 1993 S
5224938 Fenton, Jr. Jul 1993 A
5242415 Kantrowitz et al. Sep 1993 A
5246462 Bekki et al. Sep 1993 A
5249598 Schmidt Oct 1993 A
5263930 Ensminger Nov 1993 A
5281205 McPherson Jan 1994 A
5290263 Wigness et al. Mar 1994 A
5295658 Atkinson et al. Mar 1994 A
5299253 Wessels Mar 1994 A
5300048 Drewes, Jr. et al. Apr 1994 A
5309863 Leeb, Jr. May 1994 A
5312337 Flaherty et al. May 1994 A
5318545 Tucker Jun 1994 A
5320100 Herweck et al. Jun 1994 A
5328480 Melker et al. Jul 1994 A
5332398 Miller et al. Jul 1994 A
5336194 Polaschegg et al. Aug 1994 A
5338398 Szwejkowski et al. Aug 1994 A
5350360 Ensminger et al. Sep 1994 A
5352204 Ensminger Oct 1994 A
5360407 Leonard et al. Nov 1994 A
5383223 Inokuchi Jan 1995 A
5383233 Russell Jan 1995 A
5383585 Weiss Jan 1995 A
5383858 Reilly et al. Jan 1995 A
D355240 Gladfelter et al. Feb 1995 S
5387192 Glantz et al. Feb 1995 A
5394457 Leibinger et al. Feb 1995 A
5395324 Hinrichs et al. Mar 1995 A
5396925 Poli Mar 1995 A
5397329 Allen Mar 1995 A
5399168 Wadsworth, Jr. et al. Mar 1995 A
5405402 Dye et al. Apr 1995 A
5417656 Ensminger et al. May 1995 A
5421814 Geary Jun 1995 A
5423334 Jordan Jun 1995 A
5425762 Muller Jun 1995 A
5453097 Paradis Sep 1995 A
5456698 Byland et al. Oct 1995 A
5476451 Ensminger et al. Dec 1995 A
5476460 Montalvo Dec 1995 A
5476880 Cooke et al. Dec 1995 A
5484402 Saravia et al. Jan 1996 A
5503630 Ensminger et al. Apr 1996 A
5507813 Dowd et al. Apr 1996 A
5509805 Jagmin Apr 1996 A
5513637 Twiss et al. May 1996 A
5514103 Srisathapat et al. May 1996 A
5520632 Leveen et al. May 1996 A
5520643 Ensminger et al. May 1996 A
5527277 Ensminger et al. Jun 1996 A
5527278 Ensminger et al. Jun 1996 A
5527307 Srisathapat et al. Jun 1996 A
5531684 Ensminger et al. Jul 1996 A
5542923 Ensminger et al. Aug 1996 A
5545143 Fischell Aug 1996 A
5554117 Ensminger et al. Sep 1996 A
5556381 Ensminger et al. Sep 1996 A
5558641 Glantz et al. Sep 1996 A
5562617 Finch, Jr. et al. Oct 1996 A
5562618 Cai et al. Oct 1996 A
5575770 Melsky et al. Nov 1996 A
5593434 Williams Jan 1997 A
5607393 Ensminger et al. Mar 1997 A
5607407 Tolkoff et al. Mar 1997 A
5613945 Cai et al. Mar 1997 A
5620419 Lui et al. Apr 1997 A
5632729 Cai et al. May 1997 A
5637102 Tolkoff et al. Jun 1997 A
5638832 Singer et al. Jun 1997 A
5647855 Trooskin Jul 1997 A
RE35601 Eckenhoff Sep 1997 E
5662600 Watson et al. Sep 1997 A
5662612 Niehoff Sep 1997 A
5662616 Bousquet Sep 1997 A
5676146 Scarborough Oct 1997 A
5695490 Flaherty et al. Dec 1997 A
5702128 Maxim et al. Dec 1997 A
5702363 Flaherty Dec 1997 A
5704915 Melsky et al. Jan 1998 A
5707357 Mikhail et al. Jan 1998 A
5709668 Wacks Jan 1998 A
5713844 Peyman Feb 1998 A
5713858 Heruth et al. Feb 1998 A
5713859 Finch, Jr. et al. Feb 1998 A
5718382 Jaeger Feb 1998 A
5718682 Tucker Feb 1998 A
5725507 Petrick Mar 1998 A
5733336 Neuenfeldt et al. Mar 1998 A
5733400 Gore et al. Mar 1998 A
5741228 Lambrecht et al. Apr 1998 A
5743873 Cai et al. Apr 1998 A
5743891 Tolkoff et al. Apr 1998 A
5746460 Marohl et al. May 1998 A
5758667 Slettenmark Jun 1998 A
5769823 Otto Jun 1998 A
5773552 Hutchings et al. Jun 1998 A
5776188 Shepherd et al. Jul 1998 A
5792104 Speckman et al. Aug 1998 A
5792116 Berg et al. Aug 1998 A
5797886 Roth et al. Aug 1998 A
5810789 Powers et al. Sep 1998 A
5814016 Valley et al. Sep 1998 A
5824071 Nelson et al. Oct 1998 A
5830172 Leveen et al. Nov 1998 A
5833654 Powers et al. Nov 1998 A
5835563 Navab et al. Nov 1998 A
5836935 Ashton et al. Nov 1998 A
5840063 Flaherty Nov 1998 A
5843069 Butler et al. Dec 1998 A
5848989 Villani Dec 1998 A
5853394 Tolkoff et al. Dec 1998 A
5868702 Stevens et al. Feb 1999 A
5879322 Lattin et al. Mar 1999 A
5882341 Bousquet Mar 1999 A
5882353 VanBeek et al. Mar 1999 A
5895424 Steele, Sr. et al. Apr 1999 A
5897528 Schultz Apr 1999 A
5899856 Schoendorfer et al. May 1999 A
5904934 Maruyama et al. May 1999 A
5906596 Tallarida May 1999 A
5908413 Lange et al. Jun 1999 A
5908414 Otto et al. Jun 1999 A
5911706 Estabrook et al. Jun 1999 A
5913998 Butler et al. Jun 1999 A
5916263 Goicoechea et al. Jun 1999 A
5919160 Sanfilippo, II Jul 1999 A
5925017 Kriesel et al. Jul 1999 A
5925030 Gross et al. Jul 1999 A
5927345 Samson Jul 1999 A
5928197 Niehoff Jul 1999 A
5928744 Heilmann et al. Jul 1999 A
5931829 Burbank et al. Aug 1999 A
5941856 Kovacs et al. Aug 1999 A
5944023 Johnson et al. Aug 1999 A
5944688 Lois Aug 1999 A
5944698 Fischer et al. Aug 1999 A
5944712 Frassica et al. Aug 1999 A
D413672 Fogarty Sep 1999 S
5947953 Ash et al. Sep 1999 A
5951512 Dalton Sep 1999 A
5951522 Rosato et al. Sep 1999 A
5951929 Wilson Sep 1999 A
5954687 Baudino Sep 1999 A
5954691 Prosl Sep 1999 A
5957890 Mann et al. Sep 1999 A
5961497 Larkin Oct 1999 A
5968011 Larsen et al. Oct 1999 A
5970162 Kawashima Oct 1999 A
5989216 Johnson et al. Nov 1999 A
5989239 Finch et al. Nov 1999 A
5989641 Oulie Nov 1999 A
5997524 Burbank et al. Dec 1999 A
6007516 Burbank et al. Dec 1999 A
6013051 Nelson Jan 2000 A
6013058 Prosl et al. Jan 2000 A
6017331 Watts et al. Jan 2000 A
6022335 Ramadan Feb 2000 A
6033389 Cornish Mar 2000 A
6039712 Fogarty et al. Mar 2000 A
6056717 Finch et al. May 2000 A
6077756 Lin et al. Jun 2000 A
6086555 Eliasen et al. Jul 2000 A
6090066 Schnell Jul 2000 A
6099508 Bousquet Aug 2000 A
6102884 Squitieri Aug 2000 A
6113572 Gailey et al. Sep 2000 A
6120492 Finch et al. Sep 2000 A
6152909 Bagaoisan et al. Nov 2000 A
6161033 Kuhn Dec 2000 A
6171198 Troncoso et al. Jan 2001 B1
6171298 Matsuura et al. Jan 2001 B1
6186982 Gross et al. Feb 2001 B1
6190352 Haarala et al. Feb 2001 B1
6193684 Burbank et al. Feb 2001 B1
6198807 DeSena Mar 2001 B1
6200338 Solomon et al. Mar 2001 B1
6203570 Baeke Mar 2001 B1
6210366 Sanfilippo, II Apr 2001 B1
6213973 Eliasen et al. Apr 2001 B1
6228088 Miller et al. May 2001 B1
6251059 Apple et al. Jun 2001 B1
D445175 Bertheas Jul 2001 S
6261259 Bell Jul 2001 B1
6269148 Jessop et al. Jul 2001 B1
6272370 Gillies et al. Aug 2001 B1
6287293 Jones et al. Sep 2001 B1
6290677 Arai et al. Sep 2001 B1
6305413 Fischer et al. Oct 2001 B1
6306124 Jones et al. Oct 2001 B1
D450115 Bertheas Nov 2001 S
6332874 Eliasen et al. Dec 2001 B1
6355021 Nielsen et al. Mar 2002 B1
6356782 Sirimanne et al. Mar 2002 B1
6361557 Gittings et al. Mar 2002 B1
6398764 Finch, Jr. et al. Jun 2002 B1
6419680 Cosman et al. Jul 2002 B1
6450937 Mercereau et al. Sep 2002 B1
6473638 Ferek-Petric Oct 2002 B2
6475516 DiCosmo et al. Nov 2002 B2
6478783 Moorehead Nov 2002 B1
6482217 Pintor et al. Nov 2002 B1
6494867 Elver et al. Dec 2002 B1
6497062 Koopman et al. Dec 2002 B1
6500155 Sasso Dec 2002 B2
6503228 Li et al. Jan 2003 B1
6527754 Tallarida et al. Mar 2003 B1
6537255 Raines Mar 2003 B1
RE38074 Recinella et al. Apr 2003 E
6572583 Olsen et al. Jun 2003 B1
6582418 Verbeek et al. Jun 2003 B1
6592571 Verbeek et al. Jul 2003 B1
6610031 Chin Aug 2003 B1
6613002 Clark et al. Sep 2003 B1
6613662 Wark et al. Sep 2003 B2
6626936 Stinson Sep 2003 B2
6629950 Levin Oct 2003 B1
6632217 Harper et al. Oct 2003 B2
6652486 Bialecki et al. Nov 2003 B2
6652503 Bradley Nov 2003 B1
6663646 Shah Dec 2003 B1
6676633 Smith et al. Jan 2004 B2
6697664 Kienzle, III et al. Feb 2004 B2
6705316 Blythe et al. Mar 2004 B2
6719721 Okazaki et al. Apr 2004 B1
6719739 Verbeek et al. Apr 2004 B2
6726063 Stull et al. Apr 2004 B2
6738531 Funahashi May 2004 B1
6755842 Kanner et al. Jun 2004 B2
6758841 Haarala et al. Jul 2004 B2
6767356 Kanner et al. Jul 2004 B2
6784783 Scoggin et al. Aug 2004 B2
6808738 DiTizio et al. Oct 2004 B2
6826257 Sayre et al. Nov 2004 B2
6852106 Watson et al. Feb 2005 B2
6856055 Michaels et al. Feb 2005 B2
6878136 Fleury et al. Apr 2005 B2
6878137 Benchetrit Apr 2005 B2
6929631 Brugger et al. Aug 2005 B1
6949084 Marggi et al. Sep 2005 B2
6962577 Tallarida et al. Nov 2005 B2
6962580 Adams et al. Nov 2005 B2
6994315 Ryan et al. Feb 2006 B2
6997914 Smith et al. Feb 2006 B2
7008377 Beane et al. Mar 2006 B2
7008412 Maginot Mar 2006 B2
7016456 Basu et al. Mar 2006 B2
7018361 Gillespie, Jr. et al. Mar 2006 B2
7033339 Lynn Apr 2006 B1
7044942 Jolly et al. May 2006 B2
7056316 Burbank et al. Jun 2006 B1
7070591 Adams et al. Jul 2006 B2
7072704 Bucholz Jul 2006 B2
7074232 Kanner et al. Jul 2006 B2
7076305 Imran et al. Jul 2006 B2
7083593 Stultz Aug 2006 B2
7108686 Burke et al. Sep 2006 B2
7123690 Brown et al. Oct 2006 B1
7127040 Sayre et al. Oct 2006 B2
7131962 Estabrook et al. Nov 2006 B1
7140769 Kay Nov 2006 B2
7191011 Cantlon Mar 2007 B2
7198631 Kanner et al. Apr 2007 B2
7214207 Lynch et al. May 2007 B2
7214215 Heinzerling et al. May 2007 B2
7223257 Shubayev et al. May 2007 B2
7229417 Foerster et al. Jun 2007 B2
7235067 Morris et al. Jun 2007 B2
D546440 Burnside Jul 2007 S
7242982 Singhal et al. Jul 2007 B2
7248668 Galkin Jul 2007 B2
7252469 Zaluzec et al. Aug 2007 B2
7252649 Sherry Aug 2007 B2
7261705 Edoga et al. Aug 2007 B2
D554253 Kornerup Oct 2007 S
7275682 Excoffier et al. Oct 2007 B2
7276075 Callas et al. Oct 2007 B1
D556153 Burnside Nov 2007 S
7306579 Fujii Dec 2007 B2
7311702 Tallarida et al. Dec 2007 B2
7318816 Bobroff et al. Jan 2008 B2
7318818 Yashiro et al. Jan 2008 B2
7322953 Redinger Jan 2008 B2
D562442 Blateri Feb 2008 S
D562443 Zinn et al. Feb 2008 S
7331130 Schweikert Feb 2008 B2
7331948 Skarda Feb 2008 B2
7333013 Berger Feb 2008 B2
D564449 Dewberry Mar 2008 S
7347838 Kulli Mar 2008 B2
7347843 Adams et al. Mar 2008 B2
7351233 Parks Apr 2008 B2
7377915 Rasmussen et al. May 2008 B2
D574950 Zawacki et al. Aug 2008 S
7413564 Morris et al. Aug 2008 B2
D578203 Bizup Oct 2008 S
7445614 Bunodiere et al. Nov 2008 B2
D582032 Bizup et al. Dec 2008 S
7465847 Fabian Dec 2008 B2
7485148 Wozencroft et al. Feb 2009 B2
7552853 Mas et al. Jun 2009 B2
7553298 Hunt et al. Jun 2009 B2
D595892 Smith et al. Jul 2009 S
7563025 Kay Jul 2009 B2
D612479 Zawacki et al. Mar 2010 S
7713251 Tallarida et al. May 2010 B2
7785302 Powers Aug 2010 B2
7803143 Tallarida et al. Sep 2010 B2
7806888 Frassica Oct 2010 B2
7811266 Eliasen Oct 2010 B2
D629503 Caffey et al. Dec 2010 S
D634840 Lombardi, III et al. Mar 2011 S
7909804 Stats Mar 2011 B2
7947022 Amin et al. May 2011 B2
7959615 Stats et al. Jun 2011 B2
8021324 Bizup et al. Sep 2011 B2
8025639 Powers et al. Sep 2011 B2
8029482 Maniar et al. Oct 2011 B2
8075536 Gray et al. Dec 2011 B2
8092435 Beling et al. Jan 2012 B2
8147455 Butts et al. Apr 2012 B2
8172894 Schmid et al. May 2012 B2
8172896 McNamara et al. May 2012 B2
8177762 Beasley et al. May 2012 B2
8182453 Eliasen May 2012 B2
8197454 Mann et al. Jun 2012 B2
8202259 Evans et al. Jun 2012 B2
8257325 Schweikert et al. Sep 2012 B2
D676955 Orome Feb 2013 S
8377034 Tallarida et al. Feb 2013 B2
8382723 Powers et al. Feb 2013 B2
8382724 Maniar et al. Feb 2013 B2
8409153 Tallarida et al. Apr 2013 B2
8475417 Powers et al. Jul 2013 B2
8545460 Beasley et al. Oct 2013 B2
8585663 Powers et al. Nov 2013 B2
8603052 Powers et al. Dec 2013 B2
8608713 Beasley et al. Dec 2013 B2
8641676 Butts et al. Feb 2014 B2
8641688 Powers et al. Feb 2014 B2
8805478 Powers et al. Aug 2014 B2
20010016717 Haarala et al. Aug 2001 A1
20010047165 Makower et al. Nov 2001 A1
20010051766 Gazdzinski Dec 2001 A1
20010053889 Marggi et al. Dec 2001 A1
20010056266 Tallarida et al. Dec 2001 A1
20020013557 Sherry Jan 2002 A1
20020052576 Massengale May 2002 A1
20020055715 Young et al. May 2002 A1
20020095205 Edwin et al. Jul 2002 A1
20020121530 Socier Sep 2002 A1
20020138068 Watson et al. Sep 2002 A1
20020169418 Menzi et al. Nov 2002 A1
20020173769 Gray et al. Nov 2002 A1
20020173772 Olsen Nov 2002 A1
20020183846 Kuslich et al. Dec 2002 A1
20020188282 Greenberg Dec 2002 A1
20030028173 Forsberg Feb 2003 A1
20030093029 McGuckin et al. May 2003 A1
20030109856 Sherry Jun 2003 A1
20030130627 Smith et al. Jul 2003 A1
20030139812 Garcia et al. Jul 2003 A1
20030141477 Miller Jul 2003 A1
20030181878 Tallarida et al. Sep 2003 A1
20030191452 Meglin et al. Oct 2003 A1
20030208184 Burke et al. Nov 2003 A1
20030216694 Tollini Nov 2003 A1
20030217659 Yamamoto et al. Nov 2003 A1
20040006316 Patton Jan 2004 A1
20040020462 Sauler et al. Feb 2004 A1
20040020492 Dubrul et al. Feb 2004 A1
20040044306 Lynch et al. Mar 2004 A1
20040054352 Adams et al. Mar 2004 A1
20040056266 Suh et al. Mar 2004 A1
20040064110 Forsell Apr 2004 A1
20040073196 Adams et al. Apr 2004 A1
20040078000 Borchard et al. Apr 2004 A1
20040086568 Ditizio et al. May 2004 A1
20040087877 Besz et al. May 2004 A1
20040087885 Kawano et al. May 2004 A1
20040106878 Skujins et al. Jun 2004 A1
20040106891 Langan et al. Jun 2004 A1
20040106942 Taylor et al. Jun 2004 A1
20040133173 Edoga et al. Jul 2004 A1
20040156472 Galkin Aug 2004 A1
20040157952 Soffiati et al. Aug 2004 A1
20040158207 Hunn et al. Aug 2004 A1
20040167543 Mazzocchi et al. Aug 2004 A1
20040176743 Morris et al. Sep 2004 A1
20040186444 Daly et al. Sep 2004 A1
20040199129 DiMatteo Oct 2004 A1
20040199220 Cantlon Oct 2004 A1
20040204692 Eliasen Oct 2004 A1
20040204759 Blom et al. Oct 2004 A1
20040225254 Tanaka et al. Nov 2004 A1
20040254536 Conlon et al. Dec 2004 A1
20040254537 Conlon et al. Dec 2004 A1
20050010176 Dikeman et al. Jan 2005 A1
20050010286 Vijay Jan 2005 A1
20050027234 Waggoner et al. Feb 2005 A1
20050027261 Weaver et al. Feb 2005 A1
20050038390 Fago et al. Feb 2005 A1
20050049553 Triplett et al. Mar 2005 A1
20050070875 Kulessa Mar 2005 A1
20050075614 Bunodiere et al. Apr 2005 A1
20050080401 Peavey Apr 2005 A1
20050085778 Parks Apr 2005 A1
20050113806 De Carvalho et al. May 2005 A1
20050124980 Sanders Jun 2005 A1
20050131352 Conlon et al. Jun 2005 A1
20050148866 Gunderson Jul 2005 A1
20050148869 Masuda Jul 2005 A1
20050148956 Conlon et al. Jul 2005 A1
20050148957 Girard et al. Jul 2005 A1
20050152841 Sayre et al. Jul 2005 A1
20050171502 Daly et al. Aug 2005 A1
20050182857 Kong Aug 2005 A1
20050209573 Brugger et al. Sep 2005 A1
20050215874 Wang et al. Sep 2005 A1
20050241203 Lizotte et al. Nov 2005 A1
20050256451 Adams et al. Nov 2005 A1
20050256500 Fujii Nov 2005 A1
20050277899 Conlon et al. Dec 2005 A1
20050283119 Uth et al. Dec 2005 A1
20060009788 Freeman et al. Jan 2006 A1
20060017341 Hahn et al. Jan 2006 A1
20060084929 Eliasen Apr 2006 A1
20060089619 Ginggen Apr 2006 A1
20060100592 Eliasen May 2006 A1
20060116648 Hamatake Jun 2006 A1
20060171980 Helmus et al. Aug 2006 A1
20060173410 Moberg et al. Aug 2006 A1
20060173424 Conlon Aug 2006 A1
20060178647 Stats Aug 2006 A1
20060178648 Barron et al. Aug 2006 A1
20060184141 Smith et al. Aug 2006 A1
20060184142 Schon et al. Aug 2006 A1
20060217359 Wentworth et al. Sep 2006 A1
20060217659 Patton Sep 2006 A1
20060224128 Lurvey et al. Oct 2006 A1
20060224129 Beasley et al. Oct 2006 A1
20060224235 Rucker Oct 2006 A1
20060241465 Huennekens et al. Oct 2006 A1
20060247584 Sheetz et al. Nov 2006 A1
20060253076 Butts et al. Nov 2006 A1
20060264898 Beasley et al. Nov 2006 A1
20070003603 Karandikar et al. Jan 2007 A1
20070007839 Lin Jan 2007 A1
20070010881 Soye et al. Jan 2007 A1
20070016162 Burbank et al. Jan 2007 A1
20070049806 Adams et al. Mar 2007 A1
20070049876 Patton Mar 2007 A1
20070055290 Lober Mar 2007 A1
20070073250 Schneiter Mar 2007 A1
20070078391 Wortley et al. Apr 2007 A1
20070078416 Eliasen Apr 2007 A1
20070078432 Halseth et al. Apr 2007 A1
20070083111 Hossack et al. Apr 2007 A1
20070083156 Muto et al. Apr 2007 A1
20070100302 Dicarlo et al. May 2007 A1
20070112332 Harding et al. May 2007 A1
20070120683 Flippen et al. May 2007 A1
20070135775 Edoga et al. Jun 2007 A1
20070149920 Michels et al. Jun 2007 A1
20070149921 Michels et al. Jun 2007 A1
20070149947 Byrum Jun 2007 A1
20070161958 Glenn Jul 2007 A1
20070179456 Glenn Aug 2007 A1
20070185462 Byrum Aug 2007 A1
20070191773 Wojcik Aug 2007 A1
20070207335 Karandikar et al. Sep 2007 A1
20070208313 Conlon et al. Sep 2007 A1
20070219510 Zinn et al. Sep 2007 A1
20070233017 Zinn et al. Oct 2007 A1
20070233018 Bizup et al. Oct 2007 A1
20070255234 Haase et al. Nov 2007 A1
20070270691 Bailey et al. Nov 2007 A1
20070270770 Bizup Nov 2007 A1
20070276344 Bizup et al. Nov 2007 A1
20070276355 Nielsen et al. Nov 2007 A1
20070282308 Bell Dec 2007 A1
20070293800 McMaken et al. Dec 2007 A1
20070299408 Alferness et al. Dec 2007 A1
20080004642 Birk et al. Jan 2008 A1
20080008654 Clarke et al. Jan 2008 A1
20080015701 Garcia et al. Jan 2008 A1
20080039820 Sommers et al. Feb 2008 A1
20080048855 Berger Feb 2008 A1
20080108949 Beasley et al. May 2008 A1
20080114308 di Palma et al. May 2008 A1
20080133265 Silkaitis et al. Jun 2008 A1
20080137923 Spahn Jun 2008 A1
20080138387 Machiraju Jun 2008 A1
20080140025 Sheetz et al. Jun 2008 A1
20080208236 Hobbs et al. Aug 2008 A1
20080281279 Hoendervoogt et al. Nov 2008 A1
20080319398 Bizup Dec 2008 A1
20080319399 Schweikert et al. Dec 2008 A1
20080319405 Bizup Dec 2008 A1
20090024024 Zinn Jan 2009 A1
20090024098 Bizup et al. Jan 2009 A1
20090035582 Nakatani et al. Feb 2009 A1
20090118683 Hanson et al. May 2009 A1
20090156928 Evans et al. Jun 2009 A1
20090204072 Amin et al. Aug 2009 A1
20090204074 Powers et al. Aug 2009 A1
20090216216 Powers et al. Aug 2009 A1
20090221976 Linden Sep 2009 A1
20090227862 Smith et al. Sep 2009 A1
20090227951 Powers et al. Sep 2009 A1
20090227964 DiCarlo et al. Sep 2009 A1
20090264901 Franklin et al. Oct 2009 A1
20090322541 Jones et al. Dec 2009 A1
20100010339 Smith et al. Jan 2010 A1
20100042073 Oster et al. Feb 2010 A1
20100063451 Gray et al. Mar 2010 A1
20100069743 Sheetz et al. Mar 2010 A1
20100121283 Hamatake et al. May 2010 A1
20100211026 Sheetz et al. Aug 2010 A2
20100268165 Maniar et al. Oct 2010 A1
20100268174 Steinke et al. Oct 2010 A1
20110021922 Berard-Anderson et al. Jan 2011 A1
20110092921 Beling et al. Apr 2011 A1
20110118677 Wiley et al. May 2011 A1
20110183712 Eckstein et al. Jul 2011 A1
20110213700 Sant'Anselmo Sep 2011 A1
20110275930 Jho et al. Nov 2011 A1
20110276015 Powers et al. Nov 2011 A1
20110288502 Hibdon et al. Nov 2011 A1
20110311337 Amin et al. Dec 2011 A1
20120018073 Maniar et al. Jan 2012 A1
20120065622 Cornish et al. Mar 2012 A1
20120078201 Mikami Mar 2012 A1
20120191071 Butts et al. Jul 2012 A1
20120226244 Beasley et al. Sep 2012 A1
20120302969 Wiley et al. Nov 2012 A1
20130165773 Powers et al. Jun 2013 A1
20130172733 Maniar et al. Jul 2013 A1
20130225990 Powers et al. Aug 2013 A1
20130225991 Powers Aug 2013 A1
20130245574 Powers et al. Sep 2013 A1
20130338494 Wiley et al. Dec 2013 A1
20140081219 Powers et al. Mar 2014 A1
20140100534 Beasley et al. Apr 2014 A1
20140107619 Butts et al. Apr 2014 A1
20140330118 Powers et al. Nov 2014 A1
Foreign Referenced Citations (128)
Number Date Country
2008299945 Mar 2009 AU
2663853 Apr 2008 CA
2692142 Dec 2008 CA
2693972 Jan 2009 CA
102421469 Apr 2012 CN
102612343 Jul 2012 CN
3618390 Nov 1987 DE
3720414 Dec 1987 DE
10346470 May 2005 DE
0128525 Dec 1984 EP
0134745 Mar 1985 EP
0343910 Nov 1989 EP
0366814 May 1990 EP
0239244 Sep 1991 EP
0534782 Mar 1993 EP
0619101 Oct 1994 EP
1635899 Mar 2006 EP
2006019101 Dec 2006 EP
1858565 Nov 2007 EP
1874393 Jan 2008 EP
1896117 Mar 2008 EP
1998842 Dec 2008 EP
2004272 Dec 2008 EP
2018209 Jan 2009 EP
2081634 Jul 2009 EP
2164559 Mar 2010 EP
2167182 Mar 2010 EP
2180915 May 2010 EP
2190517 Jun 2010 EP
2308547 Apr 2011 EP
2320974 May 2011 EP
2324878 May 2011 EP
2324879 May 2011 EP
2324880 May 2011 EP
2365838 Sep 2011 EP
2571563 Mar 2013 EP
2601999 Jun 2013 EP
2324879 Jan 2014 EP
1509165 Jan 1968 FR
2508008 Dec 1982 FR
2809315 Nov 2001 FR
178998 May 1922 GB
749942 Jun 1956 GB
966137 Aug 1964 GB
1559140 Jan 1980 GB
2102398 Feb 1983 GB
2191701 Dec 1987 GB
2350352 Nov 2000 GB
62155857 Jul 1987 JP
62281966 Dec 1987 JP
6296633 Oct 1994 JP
2000-079168 Mar 2000 JP
2002500076 Jan 2002 JP
2003-510136 Mar 2003 JP
2004-350937 Dec 2004 JP
2006025948 Feb 2006 JP
2012-523284 Oct 2012 JP
2013-510652 Mar 2013 JP
2013-526376 Jun 2013 JP
8600213 Jan 1986 WO
8911309 Nov 1989 WO
9001958 Mar 1990 WO
9206732 Apr 1992 WO
9300945 Jan 1993 WO
9305730 Apr 1993 WO
9308986 May 1993 WO
9515194 Jun 1995 WO
9516480 Jun 1995 WO
9701370 Jan 1997 WO
9706845 Feb 1997 WO
9711726 Apr 1997 WO
9723255 Jul 1997 WO
9726931 Jul 1997 WO
9817337 Apr 1998 WO
9818506 May 1998 WO
9831417 Jul 1998 WO
9934859 Jul 1999 WO
9938553 Aug 1999 WO
9942166 Aug 1999 WO
0012171 Mar 2000 WO
0016844 Mar 2000 WO
0033901 Jun 2000 WO
0123023 Apr 2001 WO
0160444 Aug 2001 WO
0247549 Jun 2002 WO
03084832 Oct 2003 WO
03090509 Nov 2003 WO
2004004800 Jan 2004 WO
2004028611 Apr 2004 WO
2004071555 Aug 2004 WO
2004091434 Oct 2004 WO
2005037055 Apr 2005 WO
2005068009 Jul 2005 WO
2006078915 Jul 2006 WO
2006096686 Sep 2006 WO
2006116438 Nov 2006 WO
2006116613 Nov 2006 WO
2006130133 Dec 2006 WO
2006134100 Dec 2006 WO
2007041471 Apr 2007 WO
2007079024 Jul 2007 WO
2007092210 Aug 2007 WO
2007094898 Aug 2007 WO
2007098771 Sep 2007 WO
2007109164 Sep 2007 WO
2007126645 Nov 2007 WO
2007136538 Nov 2007 WO
2008008126 Jan 2008 WO
2008019236 Feb 2008 WO
2008048361 Apr 2008 WO
2008062173 May 2008 WO
2008063226 May 2008 WO
2008147760 Dec 2008 WO
2008157763 Dec 2008 WO
2009002839 Dec 2008 WO
2009012385 Jan 2009 WO
2009012395 Jan 2009 WO
2009035582 Mar 2009 WO
2009046439 Apr 2009 WO
2009046725 Apr 2009 WO
2009108669 Sep 2009 WO
2010030351 Mar 2010 WO
2010062633 Jun 2010 WO
2010118144 Oct 2010 WO
2011046604 Apr 2011 WO
2011062750 May 2011 WO
2011146649 Nov 2011 WO
2014031763 Feb 2014 WO
Non-Patent Literature Citations (321)
Entry
LAP-BAND® System Access Port Fill Guide I, “9.75/10.0 cm LAP-BAND System vs. 11 cm LAP-BAND System: For Product Manufactured Prior to Jul. 2001” BioEnterics Corporation.
Leslie et al., “A New Simple Power Injector,” Am J Roentgenol 128: 381-384, Mar. 1977.
MedComp “PortCT Technology”, display at SIR Conference (Mar. 2006), Toronto, Canada.
Navilyst Medical, Implantable Ports with PASV® Valve Technology, Product Overview, <<http://www.navilystmedical.com/Products/index.cfm/9>> last accessed Jun. 4, 2012.
Nucleus Cochlear Implant Systems; User Manual for the ESPrit 3G speech processor and accessories, Issue 2, Dec. 2001 http://www.cochlearamericas.com/PDFs/UserManualSprint.pdf.
Oct. 22, 2009 Declaration of Kelly Christian, Director of Product Development at BARD Access Systems, Inc, in support of and depicting a product on the market by Quinton Company approximately ten years prior to Oct. 22, 2009, 1 page.
PCT/US1999/028695 filed Dec. 3, 1999 International Preliminary Examination Report dated Apr. 21, 2001.
PCT/US1999/028695 filed Dec. 3, 1999 Search Report dated Apr. 11, 2000.
PCT/US2006/008022 filed Mar. 6, 2006 International Preliminary Report on Patentability dated Sep. 12, 2007.
PCT/US2006/008022 filed Mar. 6, 2006 Search Report dated Jul. 5, 2006.
PCT/US2006/008022 filed Mar. 6, 2006 Written Opinion dated Apr. 9, 2007.
PCT/US2006/008022 filed Mar. 6, 2006 Written Opinion dated Jul. 5, 2006.
PCT/US2006/015695 filed Apr. 25, 2006 Partial Search Report dated Sep. 29, 2006.
PCT/US2006/015695 filed Apr. 25, 2006 Search Report dated Jan. 11, 2007.
PCT/US2006/015695 filed Apr. 25, 2006 Written Opinion dated Jan. 11, 2007.
PCT/US2006/016056 filed Apr. 27, 2006 International Preliminary Report on Patentability dated Oct. 30, 2007.
PCT/US2006/016056 filed Apr. 27, 2006 Search Report dated Sep. 20, 2006.
PCT/US2006/016056 filed Apr. 27, 2006 Written Opinion dated Oct. 27, 2007.
PCT/US2006/016056 filed Apr. 27, 2006 Written Opinion dated Sep. 20, 2006.
PCT/US2006/049007 filed Dec. 21, 2006 International Preliminary Report on Patentability dated Jul. 1, 2008.
PCT/US2006/049007 filed Dec. 21, 2006 Search Report dated Oct. 1, 2007.
PCT/US2006/049007 filed Dec. 21, 2006 Written Opinion dated Oct. 1, 2007.
PCT/US2007/006776 filed Mar. 19, 2007 International Preliminary Report on Patentability dated Jan. 2, 2009.
PCT/US2007/006776 filed Mar. 19, 2007 Search Report, dated Dec. 18, 2007.
PCT/US2007/006776 filed Mar. 19, 2007 Written opinion, dated Dec. 18, 2007.
PCT/US2007/011015 dated May 7, 2007 Written Opinion dated Jun. 10, 2008.
PCT/US2007/011015 filed May 7, 2007 International Preliminary Report on Patentability dated Oct. 29, 2008.
PCT/US2007/011015 filed May 7, 2007 Search Report dated Jun. 10, 2008.
PCT/US2007/011456 filed May 11, 2007 Search Report dated Aug. 28, 2008.
PCT/US2007/011456 filed May 11, 2007 Written Opinion dated Aug. 28, 2008.
PCT/US2008/010520 dated Sep. 8, 2008 Search Report dated Feb. 24, 2009.
PCT/US2008/010520 filed Sep. 8, 2008 Written Opinion dated Feb. 24, 2009.
PCT/US2008/067679 filed Jun. 20, 2008 Search Report dated Sep. 30, 2008.
PCT/US2008/067679 filed Jun. 20, 2008 Written Opinion mailed on Sep. 30, 2008.
PCT/US2008/070330 filed Jul. 17, 2008 Search Report dated Dec. 1, 2008.
PCT/US2008/070330 filed Jul. 17, 2008 Written Opinion dated Dec. 1, 2008.
PCT/US2008/070345 filed Jul. 17, 2008 Search Report mailed on Dec. 1, 2008.
PCT/US2008/070345 filed Jul. 17, 2008 Written Opinion dated Dec. 1, 2008.
PCT/US2008/078976 filed Apr. 2, 2009 Search Report and Written Opinion dated Apr. 3, 2009.
PCT/US2009/062854 filed Oct. 30, 2009 International Preliminary Report on Patentability dated May 5, 2011.
PCT/US2009/062854 filed Oct. 30, 2009 International Search Report dated Dec. 10, 2009.
PCT/US2009/062854 filed Oct. 30, 2009 Search Report dated Dec. 23, 2009.
PCT/US2009/062854 filed Oct. 30, 2009 Written Opinion dated Dec. 10, 2009.
PCT/US2009/062854 filed Oct. 30, 2009 Written Opinion dated Dec. 23, 2009.
PCT/US2010/030256 filed Apr. 7, 2010 Search Report and Written Opinion dated Jun. 4, 2010.
PCT/US2010/030256 filed Apr. 7, 2010 Search Report dated Jun. 4, 2010.
U.S. Appl. No. 12/796,133, filed Jun. 8, 2010 Non-Final Office Action dated Feb. 17, 2011.
U.S. Appl. No. 12/796,133, filed Jun. 8, 2010 Notice of Allowance dated Jun. 9, 2011.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Non-Final Office Action dated Aug. 5, 2011.
U.S. Appl. No. 13/113,834, filed May 23, 2011 Non-Final Office Action dated Jul. 17, 2012.
U.S. Appl. No. 29/239,163, filed Sep. 27, 2005 entitled Injectable Power Port, listing Eddie K. Burnside as inventor.
U.S. Appl. No. 29/247,954, filed Jul. 21, 2006 entitled Injectable Power Port, listing Eddie K. Burnside as inventor.
U.S. Appl. No. 29/247,954, filed Jul. 21, 2006 Non-Final Office Action dated Apr. 6, 2007.
U.S. Appl. No. 29/247,954, filed Jul. 21, 2006 Notice of Allowability dated Jul. 30, 2007.
U.S. Appl. No. 29/284,454, filed Sep. 7, 2007 titled Implantable Port Device, listing John A. Zawacki and Annmarie Boswell as inventors, in which a Continued Prosecution Application was filed on Jan. 30, 2008.
U.S. Appl. No. 29/284,456, filed Sep. 7, 2007, titled Implantable Port Device, listing John A. Zawacki and Annemarie Boswell as inventors.
Vergara, et al., “Adverse Reactions to Contrast Medica in CT: Effects of Temperature and Ionic Property.” Radiology, vol. 199, No. 2, May 1996.
Vogelzang, Robert L., “Power Injection Through Central Venous Catheters: Physiological and Hemodynamic Considerations.” The McGaw Medical Center of Northwestern University, Feinberg School of Medicine. Jun. 23, 2004.
Wells, S. “Venous Access in Oncology and Haematology Patients: Part One.” Nursing Standard, vol. 22, No. 52, pp. 39-46, Sep. 3, 2008.
Wikipedia, “Port Catheter”, Dec. 15, 2011.
Williamson, et al., “Assessing the Adequacy of Peripherally Inserted Central Catheters for Power Injection of Intravenous Contrast Agents for CT.” Journal of Computer Assisted Tomography, vol. 6, No. 6, pp. 932-937, 2001.
U.S. Appl. No. 13/159,230, filed Jun. 13, 2011 Notice of Allowance dated Aug. 1, 2012.
U.S. Appl. No. 13/250,909, filed Sep. 30, 2011 Notice of Allowance dated Aug. 6, 2012.
U.S. Appl. No. 11/368,954, filed Mar. 6, 2006 Final Office Action dated Jan. 27, 2010.
U.S. Appl. No. 11/368,954, filed Mar. 6, 2006 Supplemental Non-final Office Action mailed Oct. 2, 2009.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Final Office Action dated Aug. 13, 2010.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Final Office Action dated Oct. 20, 2011.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Final Office Action dated Sep. 21, 2009.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Non-Final Office Action dated Apr. 26, 2010.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Non-Final Office Action dated Apr. 7, 2011.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Non-Final Office Action dated Jan. 16, 2009.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Non-Final Office Action dated Oct. 28, 2010.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Final Office Action dated Jan. 14, 2010.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Final Office Action dated Jan. 23, 2009.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Final Office Action dated Mar. 8, 2011.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Non-Final Office Action dated Jul. 1, 2009.
U.S. Appl. No. 11/380,621, filed Apr. 27, 2006 Non-Final Office Action dated Jun. 6, 2008.
U.S. Appl. No. 11/725,287, filed Mar. 19, 2007 Non-final Office Action issued on Dec. 3, 2008.
U.S. Appl. No. 11/725,287, filed Mar. 19, 2007 Non-final Office Action issued on Jun. 12, 2009.
U.S. Appl. No. 11/725,287, filed Mar. 19, 2007 Non-final Office Action issued on Mar. 29, 2010.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Final Office Action dated Oct. 13, 2011.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Non-Final Office Action dated Jun. 18, 2012.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Final Office Action dated Feb. 11, 2011.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Non-Final Office Action dated Apr. 15, 2011.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Non-Final Office Action dated Sep. 13, 2010.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Final Office Action dated Mar. 9, 2010.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Non-Final Office Action dated Dec. 13, 2010.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Non-Final Office Action dated Jul. 23, 2009.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Non-Final Office Action dated Oct. 5, 2009.
U.S. Appl. No. 12/023,280, filed Jan. 31, 2008 Notice of Allowance dated Mar. 28, 2011.
U.S. Appl. No. 12/143,377, filed Jun. 20, 2008 Final Office Action mailed Oct. 19, 2009.
U.S. Appl. No. 12/143,377, filed Jun. 20, 2008 Non-final Office Action mailed Apr. 27, 2009.
U.S. Appl. No. 12/175,182, filed Jul. 17, 2008 Non-final Office Action mailed Sep. 3, 2009.
U.S. Appl. No. 12/267,160, filed Nov. 7, 2008 Final Office Action dated Jun. 1, 2012.
U.S. Appl. No. 12/267,160, filed Nov. 7, 2008 Non-Final Office Action dated Nov. 1, 2011.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Final Office Action dated Nov. 29, 2011.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Non-Final Office Action dated Jun. 26, 2012.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Advisory Action dated Feb. 18, 2011.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Final Office Action dated Dec. 7, 2010.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Non-Final Office Action dated Feb. 18, 2010.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Non-Final Office Action dated Jul. 29, 2010.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Non-Final Office Action dated Jun. 30, 2009.
U.S. Appl. No. 12/419,957, filed Apr. 7, 2009 Notice of Allowance dated Mar. 7, 2011.
U.S. Appl. No. 12/420,007, filed Apr. 7, 2009 Final Office Action dated Feb. 18, 2010.
U.S. Appl. No. 12/420,007, filed Apr. 7, 2009 Non-Final Office Action dated Jul. 14, 2009.
U.S. Appl. No. 12/420,028, filed Apr. 7, 2009 Non-Final Office Action dated Jan. 5, 2011.
U.S. Appl. No. 12/420,028, filed Apr. 7, 2009 Notice of Allowance dated Apr. 1, 2011.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Advisory Action dated Sep. 15, 2011.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Final Office Action dated Aug. 2, 2012.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Final Office Action dated Jun. 21, 2011.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Non-Final Office Action dated Dec. 21, 2011.
U.S. Appl. No. 12/617,981, filed Nov. 13, 2009 Non-Final Office Action dated Jan. 5, 2011.
CN 201080020088.3 filed Nov. 7, 2011 First Office Action dated Mar. 4, 2013.
ECRI Institute, Healthcare Product Comparison System, Dec. 2007.
EP 06751664.1 filed Apr. 27, 2006 First Examination Report dated Jul. 11, 2013.
EP 06845998.1 filed Dec. 21, 2006 Examination Report dated May 13, 2013.
EP 10183380.4 filed Apr. 25, 2006 European Search Report dated May 22, 2013.
EP 10183382.0 filed Apr. 25, 2006 European Search Report dated May 22, 2013.
EP 10183394.5 filed Apr. 25, 2006 European Search Report dated May 22, 2013.
EP 10183398.6 filed Apr. 25, 2006 European Search Report dated May 22, 2013.
EP 10762377.9 filed Oct. 5, 2011 Office Action dated Jul. 17, 2013.
EP 13158343.7 filed Mar. 8, 2013 Extended European Search Report dated May 14, 2013.
Ethanol Lock Technique for Prevention and Treatment of Central line-Associated Bloodstream Infections (NEBRASKA) Aug. 13, 2011, Accessed: Jun. 29, 2013 http://www.nebraskamed.com/app—files/pdf/careers/education-programs/asp/tnmc—etohlock—final.pdf.
JP 2012-156976 filed Jul. 12, 2012 Submission of Documents by Third Party dated May 14, 2013.
Medcomp Dialysis and Vascular Access Products (MEDCOMP) Jun. 30, 2009, Accessed Jun. 29, 2013 http://www.medcompnet.com/products/flipbook/pdf/PN2114G—Medcomp—Catalog.pdf.
PCT/US2013/031035 filed Mar. 13, 2013 International Search Report and Written Opinion dated Jun. 3, 2013.
Takeuchi, Syuhei et al., “Safety Considerations in the Power Injection of Contrast Medium via a Totally Implantable Central Venous Access System,” Japan Journal of Interventional Radiology vol. 20, No. 1, pp. 27-30, Jan. 2005.
U.S. Appl. No. 11/380,124, filed Apr. 25, 2006 Notice of Allowance dated Apr. 29, 2013.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Advisory Action dated May 17, 2013.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Final Office Action dated Feb. 14, 2013.
U.S. Appl. No. 12/420,007, filed Apr. 7, 2009 Final Office Action dated Mar. 22, 2013.
U.S. Appl. No. 12/917,323, filed Nov. 1, 2010 Advisory Action dated Apr. 10, 2013.
U.S. Appl. No. 13/438,586, filed Apr. 3, 2012 Advisory Action dated May 29, 2013.
U.S. Appl. No. 13/438,586, filed Apr. 3, 2012 Final Office Action dated Mar. 7, 2013.
U.S. Appl. No. 13/471,219, filed May 14, 2012 Non-Final Office Action dated Jul. 10, 2013.
U.S. Appl. No. 13/571,088, filed Aug. 9, 2012 Final Office Action dated Jul. 16, 2013.
U.S. Appl. No. 13/571,088, filed Aug. 9, 2012 Non-Final Office Action dated Feb. 27, 2013.
U.S. Appl. No. 13/776,451, filed Feb. 25, 2013 Non-Final Office Action dated Jul. 24, 2013.
U.S. Appl. No. 13/853,942, filed Mar. 29, 2013 Non-Final Office Action dated Jul. 26, 2013.
U.S. Appl. No. 95/002,089, filed Aug. 20, 2012 Action Closing Prosecution dated Jun. 12, 2013.
U.S. Appl. No. 95/002,090, filed Aug. 20, 2012 Action Closing Prosecution dated Jun. 12, 2013.
U.S. Appl. No. 95/002,092, filed Aug. 20, 2012 Action Closing Prosecution dated Jun. 12, 2013.
Allergan, Inc. LAP-BAND® System Fact Sheet. © 2007.
AngioDynamics, Smart Port Guidelines for Health Care Providers, 1996.
B. Braun, Easypump Product Page, accessed May 11, 2011.
B. Braun, Port Catheter Systems Product Page, accessed May 11, 2011.
BARD Access Systems Mar. 21, 1995 Product Release to Market form for “M.R.I. Port with 8 Fr. ChronoFlexO Catheter”, “M.R.I. Port with 8Fr. ChronoFlex Catheter with Intro-Eze™”, “M.R.I. Port with 8. Fr ChronoFlex Catheter and Peel Apart”, “M.R.I. Port with 8Fr. ChronoFlex Catheter Demo Kit”. Drawings included.
Bard Healthcare Leaflet (2001).
Baxter Guidelines on Port Maintainence (Jun. 2003).
Baxter Healthport® Focus (Oct. 1999).
Baxter Healthport® Venous Systems (Oct. 2002).
Baxter Patient Information, Healthport® System (May 1999).
Baxter Therapy Systems, Baxter Healthport® Jan. 1999.
Biffi, R. et al. “Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients.” Annals of Oncology 15:296-300, 2004.
Biffi, R., et al. “Best Choice of Central Venous Insertion Site for the Prevention of Catheter-Related Complications in Adult Patients Who Need Cancer Therapy: A Randomized Trial.” Annals of Oncology, Jan. 29, 2009.
Biffi, Roberto, et al. “A Randomized, Prospective Trial of Central Venous Ports Connected to Standard Open-Ended or Groshong Catheters in Adult Oncology Patients.” American Cancer Society, vol. 92, No. 5, pp. 1204-1212, Sep. 1, 2001.
BioEnterics Corporation, LAP-BAND® “Adjustable Gastric Banding System” Product Brochure.
Braun Product Catalog (Aug. 2005).
Cardiovascular and Interventional Radiology, Review Article, “Central Venous Access Catheters: Radiological Management of Complications,” by U.K. Teichgraber, B. Gebauer, T. Benter, H.J. Wagner, published online Jul. 31, 2003.
Carlson et al., “Safety Considerations in the Power Injection of Contrast Media Via Central Venous Catheters during Computed Tomographic Examinations,” Investigative Radiology, (May 1992) 27: 337-340.
Clinical Plastic Products, “Oncology Jet Port Plus Catheter Systems” Instructions for Use, 2011.
Cook Vital-Port® Product Catalog (2000).
Costa, Nancy, “More Than Skin Deep: An Overview of Iodinated Contrast Media . . . ” Journal for the Association for Vascular Access, vol. 8, No. 4, 2003.
Costa, Nancy, “Understanding Contrast Media.” Journal of Infusion Nursing, vol. 27, No. 5, Sep./Oct. 2004.
Coyle, Douglas et al, Power Injection of Contrast Media via Peripherally Inserted Central Catheters for CT, J Vasc Interv Radiol, pp. 809-814, vol. 15, 2004.
Deltec Port Systems (Feb. and Apr. 1996).
Department of Health and Human Services, C-Port 510(k) FDA Clearance, Jun. 5, 2003.
EP 06751411 filed Apr. 25, 2006 Office Action dated Aug. 10, 2009.
EP 06751411 filed Apr. 25, 2006 Office Action dated Sep. 2, 2008.
EP 06751411 filed Apr. 25, 2006 Opposition by Aesculap AG dated Oct. 5, 2011.
EP 06751411 filed Apr. 25, 2006 Opposition by Fresenius Kabi Deutschland GmbH dated Oct. 11, 2011.
EP 06751411 filed Apr. 25, 2006 Opposition by pfm medical ag dated Oct. 12, 2011.
EP 06845998 filed Dec. 21, 2006 Office Action dated Mar. 10, 2011.
EP 06845998 filed Dec. 21, 2006 Supplementary Search Report dated Jul. 22, 2010.
EP 99964086 filed Dec. 3, 1999 Office Action dated Dec. 15, 2005.
EP 99964086 filed Dec. 3, 1999 Office Action dated Mar. 1, 2005.
EP 99964086 filed Dec. 3, 1999 Office Action dated Mar. 30, 2005.
Extravasation of Radiologic Contrast, PA-PSRS Patient Safety Advisory, vol. 1 No. 3, Sep. 2004.
Extreme Access™ Bard Access Systems, Inc. Product Brochure, 2003.
Fallscheer, et al., “Injury to the Upper Extremity Cuased by Extravasation of Contrast Medium: A True Emergency.” Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, vol. 41, pp. 26-32, 2007.
Fresenius Brochure on Intraport 1, Intraport II, and Bioport (Nov. 1998).
Gebauer, B. et al., “Contrast Media Power Injection Using Central Venous Port Catheters—Results of an In-Vitro Study,” Experimental Radiology 2005: 177: 1417-1423.
Hou, Shaw-Min et al. “Comparisons of Outcomes and Survivals for Two Central Venous Access Port Systems.” Journal of Surgical Oncology, 91:61-66, 2005.
Inamed Health, BioEnterics® LAP-BAND® “Adjustable Gastric Banding System” Product Brochure, Dec. 2003.
Johnson, Kathleen A., “Power Injectable Portal Systems.” Journal of Radiology Nursing, vol. 28, Issue 1, Mar. 2009.
JP 2007-558331 filed Mar. 6, 2006 Office Action dated May 17, 2011.
JP 2008-509056 filed Apr. 25, 2006 Office Action dated Apr. 4, 2012.
JP 2008-509056 filed Apr. 25, 2006 Office Action dated Jun. 7, 2011.
Kaste et al., “Safe use of power injectors with central and peripheral venous access devices for pediatric CT,” Pediatr Radiol (1996) 26: 499-501.
L-CATH® FOR PORTS, Luther Medical Products, Inc., Tustin, California, 2 pages, 1994.
LaMaitre Vascular “Port Implantations: using the OptiLock Implantable Port,” product information, available at http://www.lemaitre. com/specs.pop.asp, last accessed Apr. 2003, 14 pages.
LAP-BAND AP™ “System with Adjustable Gastric Banding system with OMNIFORM TN Design,” Product Brochure, Jul. 2007, 16 pages.
Bard Access Systems, BardPort and X-Port Implanted Ports Brochure, © 2007.
Bard Access Systems, BardPort, Slim Port and X-Port Instructions for Use, May 2003.
Bard Access Systems, BardPort™ Implanted Ports Patient Information, Feb. 1993.
Bard Access Systems, Ports Brochure, © 2003.
Bard Access Systems, Titanium Dome Implantable Port, http://www.bardacess.com, last accessed Jan. 10, 2012.
CN 200980153471.3 filed Jun. 30, 2011 First Office Action dated Dec. 25, 2012.
EP 06751411 filed Apr. 25, 2006 Decision Revoking the European Patent dated Aug. 1, 2012.
EP 06845998.1 filed Dec. 21, 2006 Examination Report dated Nov. 7, 2012.
EP 10762377.9 filed Oct. 5, 2011 European Search Report dated Aug. 3, 2012.
JP 2007-558331 filed Mar. 6, 2006 Office Action dated Jan. 22, 2013.
Medtronic IsoMed® Constant-Flow Infusion System: Clinical Reference Guide for Hepatic Arterial Infusion Therapy, Revised Sep. 2000.
Nucleus Cochlear Implant Systems; User Manual for the ESPrit and ESPrit 22 speech processor and accessories, Issue 3, Apr. 2000.
PCT/US11/37038 filed May 18, 2011 Written Opinion and Search Report dated Aug. 30, 2011.
PCT/US2011/037038 filed May 18, 2011 International Preliminary Report on Patentability dated Nov. 29, 2012.
PCT/US2011/037038 filed May 18, 2011 International Search Report and Written Opinion dated Aug. 30, 2011.
Request for Inter partes Reexamination of U.S. Patent No. 7,785,302, filed Aug. 20, 2012.
Request for Inter partes Reexamination of U.S. Patent No. 7,947,022, filed Aug. 20, 2012.
Request for Inter partes Reexamination of U.S. Patent No. 7,959,615, filed Aug. 20, 2012.
U.S. Appl. No. 11/937,302, filed Nov. 8, 2007 Final Office Action dated Nov. 8, 2012.
U.S. Appl. No. 12/267,160, filed Nov. 7, 2008 Examiner's Answer dated Dec. 5, 2012.
U.S. Appl. No. 12/420,007, filed Apr. 7, 2009 Non-Final Office Action dated Oct. 16, 2012.
U.S. Appl No. 12/917,323, filed Nov. 1, 2010 Final Office Action dated Jan. 29, 2013.
U.S. Appl. No. 12/917,323, filed Nov. 1, 2010 Non-Final Office Action dated Aug. 15, 2012.
U.S. Appl. No. 13/113,834, filed May 23, 2011 Final Office Action dated Nov. 23, 2012.
U.S. Appl. No. 13/438,586, filed Apr. 3, 2012 Non-Final Office Action dated Sep. 19, 2012.
U.S. Appl. No. 29/382,235, filed Dec. 30, 2010 Non-Final Office Action dated Oct. 3, 2012.
U.S. Appl. No. 29/382,246, filed Dec. 30, 2010 Notice of Allowance dated Oct. 3, 2012.
U.S. Appl. No. 95/002,089, filed Aug. 20, 2012 Office Action In and Order Granting/Denying Request for Inter Partes Reexamination dated Nov. 7, 2012.
U.S. Appl. No. 95/002,090, filed Aug. 20, 2012 Office Action In and Order Granting/Denying Request for Inter Partes Reexamination dated Nov. 7, 2012.
U.S. Appl. No. 95/002,092, filed Aug. 20, 2012 Office Action In and Order Granting/Denying Request for Inter Partes Reexamination dated Nov. 13, 2012.
PCT/US2010/030256 filed Apr. 7, 2010 Written Opinion dated Jun. 4, 2010.
PCT/US2010/054994 filed Nov. 1, 2010 Search Report dated Jan. 10, 2011.
PCT/US2010/054994 filed Nov. 1, 2010 Written Opinion dated Jan. 10, 2011.
Port-A-Cath® P.A.S. PORT® Systems by Deltec, Product Specifications, 1999.
PORT-A-CATH® “Implantable Epidural, Aterial and Peritonial Access Systems” Internet Product Listing. <<http://web.archive.org/web/20001119035900/www.deltec.com/cPacspl.htm.>> last accessed Jun. 4, 2012.
PORT-A-CATH® “Many PORT-A-CATH® System Choices” Product Brochure. © 1996 SIMS Deltec, Inc.
PORT-A-CATH® & PORT-A-CATH® II Dual-lumen Implantable Venous Access Systems Product Specifications, 2005.
PORT-A-CATH® and P.A.S. PORT® POWER P.A.C. Information Sheet, 2006.
Rappolt, Richard T., et al. “Radiopaque Codification and X-ray Identification of Ingested Drugs.” Ingestive Radiology, May-Jun. 1966.
Salis et al., “Maximal flow rates possible during power injection through currently available PICCs: An in-vitro study,” J Vasc Interv Radiol 2004; 15:275-281.
Sandstede, Joern, “Pediatric CT,” available online at www.multislice-ct.com, MultiSLICE-CT.com, version 02, May 2, 2003.
Sanelli, et al., “Safety and Feasibility of Using a Central Venous Catheter for Rapid Contrast Injection Rates.” American Journal of Radiology, vol. 183, pp. 1829-1834, Dec. 2004.
Shah, Tilak M., “Radiopaque Polymer Formulations for Medical Devices.” Medical Device and Diagnostic Industry, Mar. 2000.
Smith Medical, PORT-A-CATH® “Single-lumen Implantable Vascular Access Systems” Product Specifications, 2004.
Smith, Lisa Hartkoph, “Implanted Ports, Computed Tomography, Power Injectors, and Catheter Rupture.” Clinical Journal of Oncology Nursing, vol. 12 , No. 5. Oct. 2008.
Smiths Medical, “Smiths Medical Launches Implantable Ports for Easy Viewing Under CT Scans” Press Release, Jan. 5, 2011.
Soloman, et al., “CIN Strategies: Anticipate, Manage, Prevent.” Supplement to Imaging Economics, May 2007.
Statement of Prof. Dr. med. Karl R. Aigner, Oct. 11, 2011.
Steinbach, Barbara G. , Hardt, N. Sisson, Abbitt, Patricia L., Lanier, Linda, Caffee, H. Hollis, “Breast Implants, Common Complications, and Concurrent Breast Disease.” RadioGraphics, vol. 13, No. 1, pp. 95-118, 1993.
Sullivan et al. “Radiopaque Markers on Mammary Implants.” American Journal of Roentgenology 153(2):428, Aug. 1989.
U.S. Food and Drug Administration, “Guidance for Institutional Review Boards and Clinical Investigators 1998 Update: Medical Devices.” Version Sep. 10, 2008.
U.S. Appl. No. 60/658,518, filed Mar. 4, 2005, publicly accessible Oct. 5, 2006.
Urquiola, Javier, et al., “Using Lead Foil as a Radiopaque Marker for Computerized Tomography Imaging When Implant Treatment Planning.” The Journal of Prosthetic Dentistry, 1997.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Office Action dated Aug. 28, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Advisory Action dated Jan. 23, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Non-Final Office Action dated Feb. 13, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Non-Final Office Action dated May 20, 2009.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Non-final Office Action mailed Mar. 20, 2008.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Office Action dated Feb. 28, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Office Action dated Jul. 28, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Office Action mailed Sep. 30, 2008.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Non-Final Office Action dated May 12, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Dec. 28, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Jun. 20, 2008.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Mar. 30, 2009.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated May 28, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Nov. 28, 2006.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Oct. 31, 2007.
U.S. Appl. No. 10/374,000, filed Feb. 25, 2003 Response to Office Action dated Sep. 21, 2009.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Advisory Action dated Dec. 1, 2011.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Notice of Allowance dated Jan. 6, 2012.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Final Office Action dated Aug. 3, 2011.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Final Office Action dated Jun. 19, 2009.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Final Office Action dated Jun. 22, 2010.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Non-Final Office Action dated Feb. 13, 2008.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Non-Final Office Action dated Jan. 21, 2010.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Non-Final Office Action dated Mar. 16, 2011.
U.S. Appl. No. 11/320,223, filed Dec. 28, 2005 Non-Final Office Action dated Sep. 18, 2008.
U.S. Appl. No. 11/368,954, filed Mar. 6, 2006 Non-Final Office Action dated Jul. 21, 2009.
U.S. Appl. No. 11/368,954, filed Mar. 6, 2006 Notice of Allowance dated Jun. 24, 2010.
CN 200980153471.3 filed Jun. 30, 2011 Second Office Action dated Sep. 18, 2013.
EP 06751411 filed Apr. 25, 2006 Decision of the Technical Board of Appeal dated Jul. 24, 2013.
JP 2007-558331 filed Mar. 6, 2006 Office Action dated Aug. 20, 2013.
JP 2012-156976 filed Jul. 12, 2012 Notice of Reasons for Refusal dated Aug. 27, 2013.
MX/a/2011/004499 filed Apr. 28, 2011 First Office Action dated Jul. 25, 2013.
U.S. Appl. No. 13/438,586, filed Apr. 3, 2012 Notice of Allowance dated Sep. 16, 2013.
U.S. Appl. No. 13/776,517, filed Feb. 25, 2013 Non-Final Office Action dated Nov. 15, 2013.
Bard Access Systems, BadPort, SlimPort, X-Port Instructions for Use, 24 pages, Oct. 2012.
Bard Access Systems, PowerPort and PowerLoc CT Guide, 11 pages, Dec. 2009.
Bard Access Systems, PowerPort and PowerLoc Product Brochure, 6 pages, © 2007.
Bard Access Systems, PowerPort CT Guide, 16 pages, Mar. 2007.
Bard Access Systems, PowerPort Guidelines for CT Technologists, 1 page, Feb. 2007.
Bard Access Systems, PowerPort Guidelines for CT Technologists, 1 page, Jul. 2006.
Bard Access Systems, PowerPort Guidelines for Nurses, 1 page, Feb. 2007.
Bard Access Systems, PowerPort Guidelines for Physicians, 1 page, Feb. 2007.
Bard Access Systems, PowerPort Prescription Pad, 1 page, © 2007.
Bard Access Systems, PowerPort™ Implantable Port Product Information, © 2007.
Bard Access Systems, When in Doubt, SCOUT!, 1 page, © 2007.
Biotronik, Stratos Cardiac Resynchronization Therapy Pacemakers Technical Manual, 179 pages, © 2008.
Boston Scientific, Xcela™ Power Injectable PICC Directions for Use, 12 pages, © 2007.
CN 200980153471.3 filed Jun. 30, 2011 Third Office Action dated May 28, 2014.
CN 201080020088.3 filed Nov. 7, 2011 Second Office Action dated Nov. 21, 2013.
CN 201080051911.7 filed May 16, 2012 First Office Action dated Dec. 27, 2013.
CN 201080051911.7 filed May 16, 2012 Second Office Action dated Jul. 16, 2014.
EP 06845998.1 filed Dec. 21, 2006 Summons for Oral Proceedings dated Sep. 30, 2014.
EP 10 831 973.2 filed May 30, 2012 Extended European Search Report dated Jul. 4, 2014.
EP 10183394.5 filed Apr. 25, 2006 Opposition by Smiths Medical ASD, Inc. dated Apr. 25, 2014.
EP 13158343.7 filed Mar. 8, 2013 Summons to Attend Oral Proceedings dated Oct. 20, 2014.
JP 2012-156976 filed Jul. 12, 2012 Notice of Reasons for Refusal dated Apr. 8, 2014.
JP 2012-504826 filed Oct. 6, 2011 First Office Action dated Mar. 4, 2014.
JP 2013-209156 filed Oct. 4, 2013 Non-Final Office Action dated Oct. 7, 2014.
MX/a/2011/004499 filed Apr. 28, 2011 Second Office Action dated May 25, 2014.
PFM Medical, Xcela™ Power Injectable Port Directions for Use, 15 pages, © 2008.
STD Manufacturing, Brochure with a Hickman port, 1 page, date unknown.
U.S. Appl. No. 12/419,854, filed Apr. 7, 2009 Notice of Allowance dated Apr. 7, 2014.
U.S. Appl. No. 12/917,323, filed Nov. 1, 2010 Non-Final Office Action dated Aug. 26, 2014.
U.S. Appl. No. 13/110,734, filed May 18, 2011 Non-Final Office Action dated Jul. 7, 2014.
U.S. Appl. No. 13/776,517, filed Feb. 25, 2013 Final Office Action dated Jun. 30, 2014.
U.S. Appl. No. 13/776,517, filed Feb. 25, 2013 Notice of Allowance dated Sep. 23, 2014.
U.S. Appl. No. 13/853,956, filed Mar. 29, 2013 Non-Final Office Action dated Dec. 3, 2013.
U.S. Appl. No. 13/853,956, filed Mar. 29, 2013 Non-Final Office Action dated Sep. 15, 2014.
U.S. Appl. No. 13/853,961, filed Mar. 29, 2013 Non-Final Office Action dated Dec. 3, 2013.
U.S. Appl. No. 13/853,961, filed Mar. 29, 2013 Non-Final Office Action dated Sep. 12, 2014.
EP 06845998.1 filed Dec. 21, 2006 Examination Report dated Feb. 6, 2014.
EP 10183382.0 filed Apr. 25, 2006 Intent to Grant dated Mar. 7, 2014.
EP 11784194.0 filed Nov. 29, 2012 extended European search report dated Feb. 21, 2014.
EP 13158343.7 filed Mar. 8, 2013 Examination Report dated Feb. 4, 2014.
PCT/US2013/056019 filed Aug. 21, 2013 International Search Report and Written Opinion dated Feb. 28, 2014.
U.S. Appl. No. 13/776,517, filed Feb. 25, 2013 Non-Final Office Action dated Feb. 27, 2014.
Related Publications (1)
Number Date Country
20120259296 A1 Oct 2012 US
Provisional Applications (2)
Number Date Country
60658518 Mar 2005 US
61110507 Oct 2008 US
Divisions (1)
Number Date Country
Parent 12610084 Oct 2009 US
Child 13524712 US
Continuation in Parts (2)
Number Date Country
Parent 12420028 Apr 2009 US
Child 12610084 US
Parent 11368954 Mar 2006 US
Child 12420028 US